
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="FB70A8AB81CD960307A8AB002DDA1204.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="amjcasereps">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="The American Journal of Case Reports">
<meta name="citation_title" content="Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study">
<meta name="citation_author" content="Daniel Wang Qiu">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_author" content="Yi-Jin Lin Lee">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_author" content="Garima Tripathi">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_author_institution" content="Action Cancer Hospital, New Delhi, India">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan">
<meta name="citation_author" content="Dito Anurogo">
<meta name="citation_author_institution" content="Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar City, South Sulawesi, Indonesia">
<meta name="citation_author" content="Cheng-Fu Ni">
<meta name="citation_author_institution" content="Department of Imaging Medicine, Taipei Medical University Hospital, Taipei, Taiwan">
<meta name="citation_author" content="Wei-Chin Chang">
<meta name="citation_author_institution" content="Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_author" content="Hao-Sheng Fu">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan">
<meta name="citation_author" content="J Timothy Qiu">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_author_institution" content="Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan">
<meta name="citation_author_institution" content="International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan">
<meta name="citation_publication_date" content="2025 Apr 10">
<meta name="citation_volume" content="26">
<meta name="citation_firstpage" content="e946585">
<meta name="citation_doi" content="10.12659/AJCR.946585">
<meta name="citation_pmid" content="40208846">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/pdf/amjcaserep-26-e946585.pdf">
<meta name="description" content="Patient: Female, 44-year-old Final Diagnosis: Epithelioid peritoneal mesothelioma Symptoms: Asymptomatic Clinical Procedure: — Specialty: Obstetrics and Gynecology Rare disease Malignant peritoneal mesothelioma (MPM) is a rare and aggressive ...">
<meta name="og:title" content="Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Patient: Female, 44-year-old Final Diagnosis: Epithelioid peritoneal mesothelioma Symptoms: Asymptomatic Clinical Procedure: — Specialty: Obstetrics and Gynecology Rare disease Malignant peritoneal mesothelioma (MPM) is a rare and aggressive ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11997901">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.12659/AJCR.946585"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/amjcaserep-26-e946585.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11997901%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11997901/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11997901/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-amjcasereps.png" alt="The American Journal of Case Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to The American Journal of Case Reports" title="Link to The American Journal of Case Reports" shape="default" href="https://www.amjcaserep.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Am J Case Rep</button></div>. 2025 Apr 10;26:e946585. doi: <a href="https://doi.org/10.12659/AJCR.946585" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.12659/AJCR.946585</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Am%20J%20Case%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Am%20J%20Case%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Am%20J%20Case%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Am%20J%20Case%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Navigating Fertility Preservation in Epithelioid Peritoneal Mesothelioma: A Case Study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20DW%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Daniel Wang Qiu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Daniel Wang Qiu</span></h3>
<div class="p">
<sup>1</sup> Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20DW%22%5BAuthor%5D" class="usa-link"><span class="name western">Daniel Wang Qiu</span></a>
</div>
</div>
<sup>1,</sup><sup>B,</sup><sup>C,</sup><sup>E,</sup><sup>F,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20YJL%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Yi-Jin Lin Lee</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Yi-Jin Lin Lee</span></h3>
<div class="p">
<sup>1</sup> Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lee%20YJL%22%5BAuthor%5D" class="usa-link"><span class="name western">Yi-Jin Lin Lee</span></a>
</div>
</div>
<sup>1,</sup><sup>B,</sup><sup>C,</sup><sup>E,</sup><sup>F,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tripathi%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Garima Tripathi</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Garima Tripathi</span></h3>
<div class="p">
<sup>1</sup> Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">
<sup>2</sup> Action Cancer Hospital, New Delhi, India</div>
<div class="p">
<sup>3</sup> Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tripathi%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Garima Tripathi</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3,</sup><sup>B,</sup><sup>C,</sup><sup>E,</sup><sup>F</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Anurogo%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Dito Anurogo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Dito Anurogo</span></h3>
<div class="p">
<sup>4</sup> Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar City, South Sulawesi, Indonesia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Anurogo%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dito Anurogo</span></a>
</div>
</div>
<sup>4,</sup><sup>B,</sup><sup>C,</sup><sup>E,</sup><sup>F</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ni%20CF%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Cheng-Fu Ni</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Cheng-Fu Ni</span></h3>
<div class="p">
<sup>5</sup> Department of Imaging Medicine, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ni%20CF%22%5BAuthor%5D" class="usa-link"><span class="name western">Cheng-Fu Ni</span></a>
</div>
</div>
<sup>5,</sup><sup>C,</sup><sup>D</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20WC%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Wei-Chin Chang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Wei-Chin Chang</span></h3>
<div class="p">
<sup>6</sup> Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20WC%22%5BAuthor%5D" class="usa-link"><span class="name western">Wei-Chin Chang</span></a>
</div>
</div>
<sup>6,</sup><sup>B,</sup><sup>C,</sup><sup>D</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20HS%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Hao-Sheng Fu</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Hao-Sheng Fu</span></h3>
<div class="p">
<sup>3</sup> Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fu%20HS%22%5BAuthor%5D" class="usa-link"><span class="name western">Hao-Sheng Fu</span></a>
</div>
</div>
<sup>3,</sup><sup>B,</sup><sup>C,</sup><sup>D</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20JT%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">J Timothy Qiu</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">J Timothy Qiu</span></h3>
<div class="p">
<sup>1</sup> Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">
<sup>3</sup> Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div class="p">
<sup>7</sup> International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qiu%20JT%22%5BAuthor%5D" class="usa-link"><span class="name western">J Timothy Qiu</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>7,</sup><sup>A,</sup><sup>B,</sup><sup>C,</sup><sup>D,</sup><sup>E,</sup><sup>F,</sup><sup>G,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-amjcaserep-26-e946585">
<sup>1</sup> Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div id="af2-amjcaserep-26-e946585">
<sup>2</sup> Action Cancer Hospital, New Delhi, India</div>
<div id="af3-amjcaserep-26-e946585">
<sup>3</sup> Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div id="af4-amjcaserep-26-e946585">
<sup>4</sup> Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Makassar, Makassar City, South Sulawesi, Indonesia</div>
<div id="af5-amjcaserep-26-e946585">
<sup>5</sup> Department of Imaging Medicine, Taipei Medical University Hospital, Taipei, Taiwan</div>
<div id="af6-amjcaserep-26-e946585">
<sup>6</sup> Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div id="af7-amjcaserep-26-e946585">
<sup>7</sup> International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan</div>
<div class="author-notes p">
<div class="fn" id="fn1"><p>Authors’ Contribution:</p></div>
<div class="fn" id="fn1-amjcaserep-26-e946585">
<sup>A</sup><p class="display-inline">Study Design</p>
</div>
<div class="fn" id="fn2-amjcaserep-26-e946585">
<sup>B</sup><p class="display-inline">Data Collection</p>
</div>
<div class="fn" id="fn3-amjcaserep-26-e946585">
<sup>C</sup><p class="display-inline">Statistical Analysis</p>
</div>
<div class="fn" id="fn4-amjcaserep-26-e946585">
<sup>D</sup><p class="display-inline">Data Interpretation</p>
</div>
<div class="fn" id="fn5-amjcaserep-26-e946585">
<sup>E</sup><p class="display-inline">Manuscript Preparation</p>
</div>
<div class="fn" id="fn6-amjcaserep-26-e946585">
<sup>F</sup><p class="display-inline">Literature Search</p>
</div>
<div class="fn" id="fn7-amjcaserep-26-e946585">
<sup>G</sup><p class="display-inline">Funds Collection</p>
</div>
<div class="fn" id="fn8-amjcaserep-26-e946585">
<sup>*</sup><p class="display-inline">Daniel Wang Qiu and Yi-Jin Lin Lee contributed equally to this study</p>
</div>
<div class="fn" id="fn10"><p><strong>Conflict of interest:</strong> None declared</p></div>
<div class="fn" id="fn11"><p><strong>Financial support:</strong> This work was supported by TMU Research Center of Cancer Translational Medicine from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) Project number: DP2-TMU-113-C-06 and 113TMUH-TWS-02 from Taipei Medical University Hospital</p></div>
<div class="fn" id="c1-amjcaserep-26-e946585">
<sup>✉</sup><p class="display-inline"><strong>Corresponding Author:</strong> J. Timothy Qiu, e-mail: <span>191010@h.tmu.edu.tw</span></p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Sep 17; Accepted 2025 Jan 31; Revised 2025 Feb 25; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© Am J Case Rep, 2025</div>
<p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">CC BY-NC-ND 4.0</a>)</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11997901  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40208846/" class="usa-link">40208846</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>
Patient: Female, 44-year-old
</p>
<p>
Final Diagnosis: Epithelioid peritoneal mesothelioma
</p>
<p>
Symptoms: Asymptomatic
</p>
<p>
Clinical Procedure: —
</p>
<p>
Specialty: Obstetrics and Gynecology
</p>
<section id="sec1"><h3 class="pmc_sec_title">Objective:</h3>
<p>
<strong>Rare disease</strong>
</p></section><section id="sec2"><h3 class="pmc_sec_title">Background:</h3>
<p>Malignant peritoneal mesothelioma (MPM) is a rare and aggressive neoplasm, with low-grade epithelioid subtypes presenting diagnostic and therapeutic challenges. With nonspecific symptoms and diagnostic challenges, definitive diagnosis relies on histopathological and immunohistochemical analysis. This study reviews the current research on the epidemiology, diagnosis, and treatment of MPM, focusing on preserving fertility and achieving successful childbirth following surgery, chemotherapy, and immunotherapy, despite immune-related adverse events.</p></section><section id="sec3"><h3 class="pmc_sec_title">Case Report:</h3>
<p>We report the case of a 44-year-old nulliparous woman, initially diagnosed with a uterine leiomyoma, who was incidentally found to have MPM during surgery. Diagnostic laparoscopy and subsequent imaging revealed extensive peritoneal involvement, confirmed by histopathology and immunohistochemistry. The patient’s desire to preserve fertility complicated the treatment approach, leading to chemotherapy followed by immunotherapy, with complete disease control. Without evidence of disease recurrence or metastasis, the patient proceeded with in vitro fertilization (IVF) and embryo transfer. During an emergency cesarean section at 30 weeks 2 days of gestation, performed due to preterm premature rupture of membranes, intraabdominal residual tumors were discovered and excised. No evidence of malignancy was found elsewhere.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusions:</h3>
<p>MPM is a rare disease, often with a delayed diagnosed due to nonspecific symptoms. Treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) improve survival for operable cases, while systemic therapies and immune-checkpoint inhibitors (ICIs) are options for inoperable cases; however, further research on early-detection biomarkers and the impact of ICIs on fertility is needed to enhance clinical practice. This case highlights the intricate balance between oncologic control and fertility preservation in MPM, illustrating the need for individualized treatment strategies.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Key words:</strong> Chemotherapy, Adjuvant; Fertility Preservation; Hyperthermic Intraperitoneal Chemotherapy; Immunohistochemistry; Immunotherapy; Mesothelioma, Malignant</p></section></section><section id="sec5"><h2 class="pmc_sec_title">Introduction</h2>
<p>Malignant peritoneal mesothelioma (MPM) is a rare but aggressive neoplasm arising from the serosal membranes lining the peritoneal cavity. Although it accounts for only a small percentage of all mesothelioma cases, MPM’s clinical and pathological challenges make it a formidable disease with significant morbidity and mortality [<a href="#b1-amjcaserep-26-e946585" class="usa-link" aria-describedby="b1-amjcaserep-26-e946585">1</a>,<a href="#b2-amjcaserep-26-e946585" class="usa-link" aria-describedby="b2-amjcaserep-26-e946585">2</a>]. The incidence of MPM has shown a relatively stable trend, with a higher prevalence noted in females, contrasting with the male predominance observed in pleural mesothelioma [<a href="#b3-amjcaserep-26-e946585" class="usa-link" aria-describedby="b3-amjcaserep-26-e946585">3</a>,<a href="#b4-amjcaserep-26-e946585" class="usa-link" aria-describedby="b4-amjcaserep-26-e946585">4</a>]. The etiological role of asbestos exposure, although well-established in pleural mesothelioma, appears to be less pronounced in peritoneal cases, suggesting a multifactorial pathogenesis, including genetic predispositions such as BAP1 mutations [<a href="#b1-amjcaserep-26-e946585" class="usa-link" aria-describedby="b1-amjcaserep-26-e946585">1</a>,<a href="#b5-amjcaserep-26-e946585" class="usa-link" aria-describedby="b5-amjcaserep-26-e946585">5</a>].</p>
<p>The clinical presentation of MPM is often insidious and non-specific, leading to frequent delays in diagnosis. Symptoms such as abdominal distension, pain, and ascites are common but are not unique to this malignancy, often resulting in late-stage detection. Diagnostic modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are useful for identifying suspicious lesions, yet they lack specificity, necessitating histopathological confirmation through biopsy [<a href="#b2-amjcaserep-26-e946585" class="usa-link" aria-describedby="b2-amjcaserep-26-e946585">2</a>]. The advent of immunohistochemistry (IHC) has greatly enhanced the diagnostic accuracy of MPM, particularly in distinguishing it from other malignancies that present with similar clinical features [<a href="#b6-amjcaserep-26-e946585" class="usa-link" aria-describedby="b6-amjcaserep-26-e946585">6</a>,<a href="#b7-amjcaserep-26-e946585" class="usa-link" aria-describedby="b7-amjcaserep-26-e946585">7</a>]. However, despite advances in diagnostic techniques and therapeutic approaches, including CRS and HIPEC, the prognosis for patients with MPM remains poor, underscoring the need for ongoing research and development of more effective treatment strategies [<a href="#b8-amjcaserep-26-e946585" class="usa-link" aria-describedby="b8-amjcaserep-26-e946585">8</a>,<a href="#b9-amjcaserep-26-e946585" class="usa-link" aria-describedby="b9-amjcaserep-26-e946585">9</a>]. Therefore, an increasing number of studies have focused on the immunotherapies used in mesothelioma, with growing utilization and attention to the treatment outcomes of immune-checkpoint inhibitors (<a href="#t1-amjcaserep-26-e946585" class="usa-link">Table 1</a>).</p>
<section class="tw xbox font-sm" id="t1-amjcaserep-26-e946585"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Trials for immunotherapies used in mesothelioma.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="rows">
<thead><tr>
<th valign="middle" align="center" rowspan="1" colspan="1">
<strong>Study name</strong>
</th>
<th valign="middle" align="center" rowspan="1" colspan="1">
<strong>Year</strong>
</th>
<th valign="middle" align="center" rowspan="1" colspan="1">
<strong>Immunotherapy drugs</strong>
</th>
<th valign="middle" align="center" rowspan="1" colspan="1">
<strong>Results summary</strong>
</th>
</tr></thead>
<tbody>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">PROMISE-meso [<a href="#b10-amjcaserep-26-e946585" class="usa-link" aria-describedby="b10-amjcaserep-26-e946585">10</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2020</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">ORR: 22% vs 6%, Median PFS: 2.5 vs 3.4 months</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">KEYNOTE-158 [<a href="#b11-amjcaserep-26-e946585" class="usa-link" aria-describedby="b11-amjcaserep-26-e946585">11</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2021</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Median PFS: 6.2 months, Median OS: 12.2 months</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">CONFIRM [<a href="#b12-amjcaserep-26-e946585" class="usa-link" aria-describedby="b12-amjcaserep-26-e946585">12</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2021</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Nivolumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Median PFS: 3 months vs 1.8 months (placebo), OS: 10.2 vs 6.9 months</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">CheckMate 743 [<a href="#b13-amjcaserep-26-e946585" class="usa-link" aria-describedby="b13-amjcaserep-26-e946585">13</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2021</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Nivolumab, ipilimumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">3-year outcomes, first-line treatment</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">NIBIT-MESO-1 [<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2021</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Tremelimumab, durvalumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Median PFS (second-line): 8 months, Median OS: 16.6 months</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">MAPS-2 [<a href="#b15-amjcaserep-26-e946585" class="usa-link" aria-describedby="b15-amjcaserep-26-e946585">15</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2021</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Nivolumab, ipilimumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Disease control rate(DCR): 40–52%, Median OS: 15.9 months</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">BEAT-meso [<a href="#b16-amjcaserep-26-e946585" class="usa-link" aria-describedby="b16-amjcaserep-26-e946585">16</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2024</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Bevacizumab, atezolizumab</td>
<td valign="middle" align="left" rowspan="1" colspan="1">PFS was 9.2 months (Atezolizumab + Bevacizumab + Chemotherapy) vs 7.6 months (Bevacizumab + Chemotherapy); OS was 20.5 vs 18.1 months, ORR: 55% vs 49%</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">DREAM3R [<a href="#b17-amjcaserep-26-e946585" class="usa-link" aria-describedby="b17-amjcaserep-26-e946585">17</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2022</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Durvalumab with chemotherapy</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Ongoing phase 3 trial, results awaited</td>
</tr>
<tr>
<td valign="middle" align="left" rowspan="1" colspan="1">IND227 [<a href="#b18-amjcaserep-26-e946585" class="usa-link" aria-describedby="b18-amjcaserep-26-e946585">18</a>]</td>
<td valign="middle" align="center" rowspan="1" colspan="1">2023</td>
<td valign="middle" align="left" rowspan="1" colspan="1">Pembrolizumab + platinum + pemetrexed (CP)</td>
<td valign="middle" align="left" rowspan="1" colspan="1">CP + pembrolizumab showed improved overall survival (19.8 months vs 8.9 months) and response rate (47% vs 19%) compared to CP alone</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t1-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec6"><h2 class="pmc_sec_title">Case Report</h2>
<section id="sec7"><h3 class="pmc_sec_title">Incidental Discovery of Malignant Peritoneal Mesothelioma</h3>
<p>A 44-year-old asymptomatic nulliparous woman presented with a palpable pelvic mass. The physical examination revealed an enlarged uterus of about 10- to 12-week size, which was mobile, firm in consistency, with no uterine or forniceal tenderness, and mild swelling in the right pubic area. The primary diagnosis is an anterior wall uterine leiomyoma, measuring 112×94×108 mm, accompanied by ascites measuring 65×42 mm and a 20×14 mm mass, as identified via gynecological sonography on January 30, 2010. During a laparotomic myomectomy performed on February 17, 2020, an incidental discovery of a pelvic tumor was made.</p>
<p>This tumor appeared as a cauliflower-like lesion disseminated across the right pelvic wall, cul-de-sac, anterior uterine surface, bladder, and colon (<a href="#f1-amjcaserep-26-e946585" class="usa-link">Figure 1</a>). A biopsy of the sigmoid colon serosa yielded a 0.8 cm sample, which pathologically demonstrated proliferative mesothelial cells without significant atypia or necrosis. A post-myomectomy CT scan (<a href="#f2-amjcaserep-26-e946585" class="usa-link">Figure 2</a>) revealed seeding in the lower pelvis, characterized by multiple small, heterogeneous, enhancing nodules on the peritoneum and a prominent soft-tissue mass in the right adnexa.</p>
<figure class="fig xbox font-sm" id="f1-amjcaserep-26-e946585"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/0dd78cd7c3fe/amjcaserep-26-e946585-g001.jpg" loading="lazy" height="420" width="720" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/f1-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic diagram of the tumor invasion site. The stage IIIb tumors have invaded deeper tissues in nearby organs and distant lymph nodes. Sites involved by peritoneal mesothelioma: peritoneum, abdominal wall, omentum, lymph nodes, large intestine, mesentery and bladder.</p></figcaption></figure><figure class="fig xbox font-sm" id="f2-amjcaserep-26-e946585"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/761cfcc0c9a8/amjcaserep-26-e946585-g002.jpg" loading="lazy" height="300" width="780" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/f2-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Postoperative pelvic CT scan (February 26<sup>th</sup>, 2020). (<strong>A</strong>) The scan reveals moderate ascites (white arrow) and nonspecific peritoneal thickening. (<strong>B</strong>) The scan shows small enhancing nodules on the peritoneal membrane, with notable soft-tissue thickening in the right adnexa compared to the left.</p></figcaption></figure><p>Histopathological examination identified bland mesothelial cells and no invasions (<a href="#f3-amjcaserep-26-e946585" class="usa-link">Figure 3A–3C</a>), with immunohistochemistry showing no evidence of significant staining loss (<a href="#f3-amjcaserep-26-e946585" class="usa-link">Figure 3D, 3E</a>). The differential diagnosis included well-differentiated papillary mesothelioma, epithelioid peritoneal mesothelioma, and florid mesothelial hyperplasia, and a well-differentiated papillary mesothelioma was highly suspected. The management plan recommending debulking surgery followed by HIPEC was proposed by the multidiscipline tumor board. However, the patient declined the suggested treatment due to her wish to preserve fertility. Six months after the initial presentation, she returned to the clinic for embryo transfer surgery, aiming to address her fertility aspirations. During the preoperative evaluation, the incidental finding of ascites prompted a referral to Taipei Medical University Hospital for further assessment. A CT scan performed on July 8, 2020 revealed a newly-enlarged right inguinal lymph node measuring 1.8 cm, along with a persistent soft-tissue density in the adnexa and a stable peritoneal nodule, with no significant interval changes compared to the CT scan conducted on February 26, 2020.</p>
<figure class="fig xbox font-sm" id="f3-amjcaserep-26-e946585"><h4 class="obj_head">Figure 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/e464c777e6da/amjcaserep-26-e946585-g003.jpg" loading="lazy" height="384" width="771" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/f3-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pathology report of pelvic tissue (February 17<sup>th</sup>, 2020). (<strong>A–C</strong>). Histology showed bland mesothelial cells and no invasions. The diagnosis of well-differentiated papillary mesothelioma was highly suspected. (<strong>D, E</strong>) Immunohistochemical analysis demonstrated diffuse positivity for (<strong>D</strong>) calretinin and (<strong>E</strong>) BAP1. Notably, the BAP1 stain indicated a preserved nuclear staining pattern.</p></figcaption></figure><p>Subsequent diagnostic laparoscopy included the excision of tumors from the small intestine and omentum, with the tumors measuring 1 cm and 2 cm, respectively. Notably, the tumor in the omentum exhibited invasion into the muscularis propria. Additionally, miliary tumors were observed on the right pelvic peritoneum, cul-de-sac, and diaphragm, accompanied by the presence of dark-brownish ascites. Histopathological examination of specimens (<a href="#f4-amjcaserep-26-e946585" class="usa-link">Figure 4</a>) from the peritoneum, large intestine, and small intestine revealed proliferative mesothelial cells with a finely granular chromatin pattern. Invasion into the subserosa and muscularis propria of the large intestine and omentum was confirmed. Immunohistochemical staining was positive for calretinin and BAP1, consistent with a final diagnosis of low-grade epithelioid peritoneal mesothelioma, staged as pT3NxMx (IIIB).</p>
<figure class="fig xbox font-sm" id="f4-amjcaserep-26-e946585"><h4 class="obj_head">Figure 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/9213b0be240a/amjcaserep-26-e946585-g004.jpg" loading="lazy" height="361" width="770" alt="Figure 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/f4-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pathology report (July 16<sup>th</sup>, 2020). (<strong>A</strong>) Histopathological examination of the peritoneal specimen revealed mild nuclear atypia with a finely granular chromatin pattern. (<strong>B, C</strong>) Immunohistochemical (IHC) staining demonstrated both nuclear and cytoplasmic positivity for calretinin, with preserved nuclear staining observed for BAP1. (<strong>D, E</strong>) The specimen from the large intestine exhibited papillary growth and glandular differentiation. Notably, there was evidence of stromal invasion extending into the subserosa and muscularis propria, indicative of malignant transformation.</p></figcaption></figure></section><section id="sec8"><h3 class="pmc_sec_title">Oncological Course and Treatment</h3>
<p>Following the diagnostic procedure, the patient elected to undergo chemotherapy instead of debulking surgery. She subsequently received 5 cycles of adjuvant chemotherapy, consisting of carboplatin at 5 AUC and paclitaxel at a dose of 175 mg/m<sup>2</sup>, administered every 3 weeks between August 2020 and November 2020. The chemotherapy regimen was generally well-tolerated, with the patient experiencing only minor adverse effects, notably alopecia. No significant adverse effects such as pancytopenia, nausea, or vomiting were reported during treatment.</p>
<p>However, a follow-up fluorodeoxyglucose-positron emission tomography (FDG-PET CT) scan performed on October 15, 2020 (<a href="#f5-amjcaserep-26-e946585" class="usa-link">Figure 5</a>), during the chemotherapy course indicated disease progression. The scan revealed an increase in the size of the right inguinal lymph node, suggesting progression of the underlying pathology.</p>
<figure class="fig xbox font-sm" id="f5-amjcaserep-26-e946585"><h4 class="obj_head">Figure 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/bf9226d6214a/amjcaserep-26-e946585-g005.jpg" loading="lazy" height="195" width="720" alt="Figure 5."></a></p>
<div class="p text-right font-secondary"><a href="figure/f5-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>FDG-PET CT interpretation (October 15<sup>th</sup>, 2020). (<strong>A–C</strong>) The PET CT shows metabolic activity in the pelvis and a 1.2-cm low-FDG nodule in the umbilical area, consistent with post-treatment response in peritoneal mesothelioma.</p></figcaption></figure><p>On November 5, 2020, the patient underwent a laparoscopic fertility-sparing surgery aimed at excising malignant tumors from the abdominal wall and omentum. This procedure included HIPEC and excision of the right inguinal tumor (<a href="#f6-amjcaserep-26-e946585" class="usa-link">Figure 6</a>). During the operation, multiple miliary tumors, ranging from 0.1 to 1 cm in size, were identified and excised from the abdominal wall and peritoneum. The right inguinal lymph node was also excised, and HIPEC was performed with paclitaxel (175 mg/m<sup>2</sup>) for 90 minutes. Pathological analysis of the excised specimens confirmed the presence of epithelioid-type mesothelioma involving the right pelvic cavity and omentum (<a href="#f7-amjcaserep-26-e946585" class="usa-link">Figure 7</a>).</p>
<figure class="fig xbox font-sm" id="f6-amjcaserep-26-e946585"><h4 class="obj_head">Figure 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g006.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/aba634ef5ea1/amjcaserep-26-e946585-g006.jpg" loading="lazy" height="672" width="780" alt="Figure 6."></a></p>
<div class="p text-right font-secondary"><a href="figure/f6-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Laparoscopic fertility-sparing surgery with HIPEC (November 5<sup>th</sup>, 2020): Intraoperative findings and surgical notes. (<strong>A</strong>) The PCI score was 14, indicating extensive peritoneal involvement, with tumors mainly in the pelvis and lower abdomen. The diagram shows numerous nodules over 1 cm. (<strong>B</strong>) Surgical exploration revealed multiple miliary tumors (0.1–1 cm) scattered across the peritoneum, mesentery, omentum, and abdominal wall, indicating widespread tumor dissemination. (<strong>C</strong>) The images show a hydatidiform lesion in the upper quadrant and tumor spread into the pelvic region, highlighting extensive abdominal disease (ovaries).</p></figcaption></figure><figure class="fig xbox font-sm" id="f7-amjcaserep-26-e946585"><h4 class="obj_head">Figure 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/8318a2f9be5d/amjcaserep-26-e946585-g007.jpg" loading="lazy" height="540" width="780" alt="Figure 7."></a></p>
<div class="p text-right font-secondary"><a href="figure/f7-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pathological findings (November 6<sup>th</sup>, 2020). (<strong>A</strong>) The pelvic specimen shows marked adhesion and stromal invasion with a papillary growth pattern, consistent with epithelioid mesothelioma. (<strong>B</strong>) Immunohistochemical staining confirmed the diagnosis, showing strong, diffuse positivity for calretinin, indicating a mesothelial origin of the tumor. (<strong>C</strong>) WT-1 and (<strong>D</strong>) BAP1 were positive. WT-1 is linked to mesotheliomas, while BAP1 positivity, uncommon in aggressive cases, indicates a less aggressive tumor subtype.</p></figcaption></figure><p>After chemotherapy proved ineffective, the patient underwent surgery again, combined with HIPEC (hyperthermic intraperitoneal chemotherapy) to remove visible tumors. During shared decision-making regarding treatment options, the patient declined further chemotherapy (including pemetrexed) and opted for dual immunotherapy instead. She was started on immunotherapy, receiving 3 cycles of nivolumab (100 mg) and ipilimumab (50 mg) every 4 weeks from December 2020 to February 2021. Throughout the immunotherapy course, she tolerated the treatment well, without experiencing significant adverse effects such as nausea, vomiting, or fever. Additionally, her estrogen and follicle-stimulating hormone (FSH) levels remained within normal ranges, suggesting preserved ovarian function despite the aggressive treatment regimen. Subsequent follow-up imaging studies, including CT and MRI scans, demonstrated stable soft-tissue densities in the bilateral adnexa. Importantly, there were no signs of malignancy or metastasis in the lungs or brain, providing reassurance of disease stability.</p></section><section id="sec9"><h3 class="pmc_sec_title">In vitro Fertilization and Obstetric Course</h3>
<p>With no evidence of disease recurrence or metastasis, the patient proceeded with IVF and embryo transfer. This intervention culminated in a successful pregnancy in May 2022. Comprehensive prenatal evaluations, conducted at local hospital, confirmed the absence of gestational diabetes mellitus, preeclampsia, or proteinuria. Additionally, high-resolution ultrasound examinations confirmed normal fetal anatomical development.</p>
<p>However, at 29 weeks of gestation, she had preterm premature rupture of membranes (PPROM). She was subsequently admitted to our hospital for tocolytic therapy, receiving ritodrine and nifedipine to inhibit uterine contractions. To prevent infection, antibiotics were administered alongside beta-methasone to accelerate fetal lung maturation and magnesium sulfate for neuroprotection. Despite 5 days of intensive tocolysis, the patient continued to experience frequent uterine contractions. Concurrently, the amniotic fluid index (AFI) decreased significantly from an initial measurement of 4.82 at admission to 0, accompanied by bloody vaginal discharge and uterine contraction. Given these developments, an emergency cesarean section was performed at a gestational age of 30 weeks 2 days on Dec. 12, 2022. She delivered a female infant who weighed 1378 g, with Apgar score 7/9 at 1 and 5 mins. The neonate was kept in the intensive care unit with oxygen therapy, which was withdrawn when the oxygen saturation level was greater than 90%. She continued to feed well and grow appropriately during her stay. No imaging studies were required and she was subsequently discharged.</p>
<p>Following the delivery, a secondary surgical exploration by gynecologic oncologists was conducted to evaluate any potential tumor progression or metastasis within the abdominal cavity. Intraoperatively, multiple tumor seedings were identified, ranging from 0.5 to 1.5 cm in size, distributed across the small intestine, mesentery, and peritoneum. These lesions were excised, along with residual tumors located on the rectum, peritoneal wall, and bladder base. Biopsies were obtained, and pathological examination confirmed the presence of epithelioid peritoneal mesothelioma. Postoperatively, the patient remained stable without any anticancer treatment and was discharged with a plan for outpatient follow-up. The most recent imaging studies, including CT and MRI scans, revealed a uterine myoma measuring 4.5 cm, with no further evidence of malignancy elsewhere. The treatment timeline is presented in <a href="#f8-amjcaserep-26-e946585" class="usa-link">Figure 8</a>.</p>
<figure class="fig xbox font-sm" id="f8-amjcaserep-26-e946585"><h4 class="obj_head">Figure 8.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11997901_amjcaserep-26-e946585-g008.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4da9/11997901/5696614b7f84/amjcaserep-26-e946585-g008.jpg" loading="lazy" height="300" width="756" alt="Figure 8."></a></p>
<div class="p text-right font-secondary"><a href="figure/f8-amjcaserep-26-e946585/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Treatment timeline of the patient.</p></figcaption></figure></section></section><section id="sec10"><h2 class="pmc_sec_title">Discussion</h2>
<section id="sec11"><h3 class="pmc_sec_title">Clinical Presentation, Diagnosis and Management of Malignant Peritoneal Mesothelioma (MPM)</h3>
<p>Malignant mesothelioma is a rare but highly aggressive neoplasm originating from the serosal membranes. Its prevalence varies by anatomical site, with the pleura being the most commonly affected, followed by the peritoneum, pericardium, and testis, in descending order of frequency [<a href="#b4-amjcaserep-26-e946585" class="usa-link" aria-describedby="b4-amjcaserep-26-e946585">4</a>,<a href="#b10-amjcaserep-26-e946585" class="usa-link" aria-describedby="b10-amjcaserep-26-e946585">10</a>]. In contrast to the male predominance observed in pleural mesothelioma, the prevalence of malignant peritoneal mesothelioma (MPM) in females ranges between 30% to 50% in the United States [<a href="#b11-amjcaserep-26-e946585" class="usa-link" aria-describedby="b11-amjcaserep-26-e946585">11</a>]. While MPM is often associated with industrial pollutants, particularly asbestos exposure, this association is less pronounced than in pleural mesothelioma [<a href="#b12-amjcaserep-26-e946585" class="usa-link" aria-describedby="b12-amjcaserep-26-e946585">12</a>–<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>]. This suggests that MPM can develop even in the absence of significant asbestos exposure, potentially due to germline BAP1 heterozygous mutations, which are hypothesized to increase susceptibility to low levels of asbestos exposure [<a href="#b15-amjcaserep-26-e946585" class="usa-link" aria-describedby="b15-amjcaserep-26-e946585">15</a>]. MPM is histologically classified into 3 subtypes: epithelioid, sarcomatous, and biphasic. Among these, the epithelioid subtype is the most prevalent and is associated with the most favorable prognosis [<a href="#b11-amjcaserep-26-e946585" class="usa-link" aria-describedby="b11-amjcaserep-26-e946585">11</a>,<a href="#b16-amjcaserep-26-e946585" class="usa-link" aria-describedby="b16-amjcaserep-26-e946585">16</a>]. MPM is classified into 2 grades: low-grade and high-grade [<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>].</p>
<p>However, the clinical presentation of MPM is often nonspecific, with symptoms such as abdominal distension, pain, early satiety, anorexia, nausea, and weight loss, which do not distinctly point to this malignancy [<a href="#b17-amjcaserep-26-e946585" class="usa-link" aria-describedby="b17-amjcaserep-26-e946585">17</a>]. As a result, MPM is frequently discovered incidentally during routine examinations or unrelated surgical procedures, leading to delayed diagnosis and, consequently, advanced disease with abdominal seeding in many patients [<a href="#b11-amjcaserep-26-e946585" class="usa-link" aria-describedby="b11-amjcaserep-26-e946585">11</a>,<a href="#b18-amjcaserep-26-e946585" class="usa-link" aria-describedby="b18-amjcaserep-26-e946585">18</a>].</p>
<p>When malignancy is suspected, initial imaging typically involves computed tomography (CT) or magnetic resonance imaging (MRI). While these modalities effectively identify areas of concern, they lack the specificity required to definitively diagnose the type of cancer [<a href="#b19-amjcaserep-26-e946585" class="usa-link" aria-describedby="b19-amjcaserep-26-e946585">19</a>].</p>
<p>Positron emission tomography (PET) scans are often employed for staging purposes but do not offer definitive identification of MPM. Given the low diagnostic specificity of imaging studies, the definitive diagnosis of MPM relies on tissue sampling via CT-guided core-needle biopsy or laparoscopic biopsy, followed by histopathological examination and immunohistochemical analysis [<a href="#b18-amjcaserep-26-e946585" class="usa-link" aria-describedby="b18-amjcaserep-26-e946585">18</a>].</p>
<p>Hematoxylin-eosin (H&amp;E) staining provides initial identification of the MPM subtype but is insufficient for distinguishing MPM from other malignancies such as non-small cell lung carcinoma, renal cell carcinoma, and ovarian carcinoma [<a href="#b20-amjcaserep-26-e946585" class="usa-link" aria-describedby="b20-amjcaserep-26-e946585">20</a>]. Consequently, immunohistochemistry (IHC) is essential in differentiating mesothelioma from its malignant mimics and other mesothelial proliferations [<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>].</p>
<p>A comprehensive IHC panel, typically including at least 2 mesothelial markers and 2 carcinoma-related markers, is employed to confirm the diagnosis [<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>]. Commonly utilized mesothelial markers include calretinin, WT-1, podoplanin, BAP1, MTAP, and CDKN2A. These markers are crucial for confirming the mesothelial origin of the tumor. Additionally, carcinoma-related markers such as CEA, claudin-4, Ber-EP4, MOC-31, and TTF-1 are utilized to further refine the diagnosis, distinguishing MPM from other carcinomas [<a href="#b14-amjcaserep-26-e946585" class="usa-link" aria-describedby="b14-amjcaserep-26-e946585">14</a>,<a href="#b16-amjcaserep-26-e946585" class="usa-link" aria-describedby="b16-amjcaserep-26-e946585">16</a>]. This immunohistochemical approach not only aids in accurate diagnosis but also has prognostic implications, particularly in the context of determining the most appropriate therapeutic strategy.</p>
<p>In recent years, advances in molecular diagnostics have further enhanced our understanding of malignant peritoneal mesothelioma (MPM), providing deeper insights into its pathogenesis and potential therapeutic targets. Genetic alterations, particularly involving the BAP1 gene, have emerged as significant contributors to the development and progression of MPM. BAP1 (BRCA1-associated protein 1) is a tumor-suppressor gene that plays a crucial role in various cellular processes, including DNA repair, cell cycle regulation, and chromatin remodeling [<a href="#b21-amjcaserep-26-e946585" class="usa-link" aria-describedby="b21-amjcaserep-26-e946585">21</a>]. Loss-of-function mutations in BAP1 are found in many MPM cases, especially in those without a history of asbestos exposure, highlighting its role in the tumorigenesis of mesothelioma [<a href="#b22-amjcaserep-26-e946585" class="usa-link" aria-describedby="b22-amjcaserep-26-e946585">22</a>].</p>
<p>The identification of BAP1 mutations has not only provided insights into the molecular underpinnings of MPM but also opened avenues for personalized medicine. Patients with BAP1 mutations may benefit from targeted therapies aimed at exploiting specific vulnerabilities associated with this genetic alteration [<a href="#b23-amjcaserep-26-e946585" class="usa-link" aria-describedby="b23-amjcaserep-26-e946585">23</a>]. For instance, recent studies have explored the potential of PARP inhibitors, which target DNA repair pathways, in BAP1-mutated mesotheliomas [<a href="#b24-amjcaserep-26-e946585" class="usa-link" aria-describedby="b24-amjcaserep-26-e946585">24</a>]. These developments are a significant step forward in the treatment of MPM, which has historically been challenging due to the disease’s resistance to conventional chemotherapy and radiation therapy.</p>
<p>Another promising area of research in MPM management is the use of immunotherapy, particularly immune-checkpoint inhibitors. Immune-checkpoint blockade, which involves targeting inhibitory receptors such as PD-1, PD-L1, and CTLA-4 on T cells, has revolutionized the treatment of various solid tumors [<a href="#b25-amjcaserep-26-e946585" class="usa-link" aria-describedby="b25-amjcaserep-26-e946585">25</a>]. The potential synergy between immunotherapy and other modalities, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), is also under investigation, with the goal of improving patient outcomes and prolonging survival [<a href="#b26-amjcaserep-26-e946585" class="usa-link" aria-describedby="b26-amjcaserep-26-e946585">26</a>].</p>
<p>Additionally, comprehensive genomic profiling can identify actionable mutations and inform the selection of targeted therapies, moving towards a more personalized treatment approach. Despite these advancements, the management of MPM remains complex and multifaceted, requiring a multidisciplinary approach. Optimal patient care involves not only accurate diagnosis and staging but also consideration of various treatment modalities, including surgery, chemotherapy, radiation, and emerging therapies such as targeted agents and immunotherapy. The ongoing development of clinical trials and translational research is critical to further refining therapeutic strategies and improving the prognosis of patients with MPM.</p></section><section id="sec12"><h3 class="pmc_sec_title">CRS and HIPEC in Treatment of Malignant Peritoneal Mesothelioma</h3>
<p>Malignant peritoneal mesothelioma (MPM) remains a challenging and aggressive malignancy with limited treatment options. The current therapeutic strategies for MPM include surgical intervention and systemic therapies [<a href="#b27-amjcaserep-26-e946585" class="usa-link" aria-describedby="b27-amjcaserep-26-e946585">27</a>], with cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) emerging as the cornerstone of treatment in select patients. This approach is particularly recommended for individuals with medically operable, diffuse peritoneal mesothelioma and those demonstrating good performance status, following a comprehensive multidisciplinary evaluation [<a href="#b27-amjcaserep-26-e946585" class="usa-link" aria-describedby="b27-amjcaserep-26-e946585">27</a>–<a href="#b29-amjcaserep-26-e946585" class="usa-link" aria-describedby="b29-amjcaserep-26-e946585">29</a>].</p>
<p>CRS aims to surgically remove all visible tumor deposits within the peritoneal cavity, thereby reducing the tumor burden to the lowest possible level. This is followed by HIPEC, which involves the circulation of heated chemotherapeutic agents directly within the abdominal cavity to target residual microscopic disease. The rationale behind HIPEC lies in the enhanced penetration of chemotherapeutic agents at elevated temperatures, which may also potentiate their cytotoxic effects on cancer cells. This combined modality treatment has been shown to significantly improve survival outcomes in patients with MPM [<a href="#b28-amjcaserep-26-e946585" class="usa-link" aria-describedby="b28-amjcaserep-26-e946585">28</a>,<a href="#b29-amjcaserep-26-e946585" class="usa-link" aria-describedby="b29-amjcaserep-26-e946585">29</a>].</p>
<p>Several studies have demonstrated the efficacy of CRS and HIPEC, with median overall survival for patients undergoing these procedures ranging from 38.4 to 63.2 months [<a href="#b29-amjcaserep-26-e946585" class="usa-link" aria-describedby="b29-amjcaserep-26-e946585">29</a>–<a href="#b33-amjcaserep-26-e946585" class="usa-link" aria-describedby="b33-amjcaserep-26-e946585">33</a>]. The 3-year and 5-year survival rates reported in the literature vary between 42% and 60% and 42% and 50.2%, respectively. These findings underscore the potential of CRS and HIPEC not only to extend survival but also to offer durable control of disease in a subset of patients with MPM [<a href="#b30-amjcaserep-26-e946585" class="usa-link" aria-describedby="b30-amjcaserep-26-e946585">30</a>–<a href="#b33-amjcaserep-26-e946585" class="usa-link" aria-describedby="b33-amjcaserep-26-e946585">33</a>].</p>
<p>The decision to pursue CRS and HIPEC is based on multiple factors, including the depth of tumor invasion, histological subtype, patient age, and overall health status [<a href="#b29-amjcaserep-26-e946585" class="usa-link" aria-describedby="b29-amjcaserep-26-e946585">29</a>]. The success of this approach is highly dependent on the completeness of cytoreduction, with more extensive tumor debulking correlating with better outcomes. However, the procedure is not without risks, and patient selection remains critical to optimizing results. The potential benefits of this aggressive therapy must be weighed against the risks, particularly in patients with comorbidities or advanced age.</p></section><section id="sec13"><h3 class="pmc_sec_title">Systemic Therapy in the Management of Malignant Peritoneal Mesothelioma</h3>
<p>For patients with malignant peritoneal mesothelioma (MPM) who are not candidates for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), systemic therapy remains the cornerstone of treatment. This group includes individuals who are deemed inoperable due to factors such as extensive disease involvement, including bicavitary dissemination, or those with histological subtypes associated with a poorer prognosis, such as sarcomatoid or biphasic histology [<a href="#b34-amjcaserep-26-e946585" class="usa-link" aria-describedby="b34-amjcaserep-26-e946585">34</a>–<a href="#b36-amjcaserep-26-e946585" class="usa-link" aria-describedby="b36-amjcaserep-26-e946585">36</a>].</p>
<p>Systemic therapy typically involves use of chemotherapeutic agents aimed at controlling tumor growth, alleviating symptoms, and prolonging survival. Pemetrexed, a multi-targeted antifolate, has emerged as a key agent in the systemic treatment of MPM, particularly when combined with platinum-based chemotherapy such as cisplatin [<a href="#b37-amjcaserep-26-e946585" class="usa-link" aria-describedby="b37-amjcaserep-26-e946585">37</a>]. This regimen is commonly employed as a first-line therapy, especially for patients who are not eligible for surgical intervention [<a href="#b38-amjcaserep-26-e946585" class="usa-link" aria-describedby="b38-amjcaserep-26-e946585">38</a>].</p>
<p>Several clinical trials have evaluated the efficacy of pemetrexed-based regimens in MPM, both as monotherapy and in combination with cisplatin. These studies have reported median overall survival ranging from approximately 13 to 16.6 months, demonstrating the potential of systemic therapy to offer meaningful clinical benefits in this challenging patient population [<a href="#b34-amjcaserep-26-e946585" class="usa-link" aria-describedby="b34-amjcaserep-26-e946585">34</a>,<a href="#b36-amjcaserep-26-e946585" class="usa-link" aria-describedby="b36-amjcaserep-26-e946585">36</a>,<a href="#b39-amjcaserep-26-e946585" class="usa-link" aria-describedby="b39-amjcaserep-26-e946585">39</a>–<a href="#b41-amjcaserep-26-e946585" class="usa-link" aria-describedby="b41-amjcaserep-26-e946585">41</a>]. Additionally, the 1-year survival rates for patients receiving these regimens have been reported to range between 41.5% and 51.4% [<a href="#b42-amjcaserep-26-e946585" class="usa-link" aria-describedby="b42-amjcaserep-26-e946585">42</a>]. These outcomes, while modest compared to those achieved with CRS and HIPEC, underscore the importance of systemic therapy in managing patients with advanced or inoperable MPM.</p>
<p>In recent years, ongoing research has sought to optimize systemic treatment strategies for MPM, including the exploration of novel combinations and the integration of emerging therapies such as immunotherapy. Immune-checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown promise in other mesothelioma subtypes and are now being investigated in the context of peritoneal mesothelioma [<a href="#b43-amjcaserep-26-e946585" class="usa-link" aria-describedby="b43-amjcaserep-26-e946585">43</a>,<a href="#b44-amjcaserep-26-e946585" class="usa-link" aria-describedby="b44-amjcaserep-26-e946585">44</a>].</p>
<p>Despite these advances, the management of MPM with systemic therapy remains complex, and response rates vary depending on factors such as tumor biology and patient performance status. Personalized approaches that incorporate molecular profiling and the identification of predictive biomarkers are increasingly recognized as essential in guiding treatment decisions and maximizing therapeutic efficacy.</p></section><section id="sec14"><h3 class="pmc_sec_title">The Role of Immune-Checkpoint Inhibitors in Treatment of Peritoneal Mesothelioma</h3>
<p>The exploration of ICIs in the treatment of peritoneal mesothelioma, although constrained by small sample sizes, has shown promising potential. Immune-checkpoint blockade, particularly targeting the PD-1/PD-L1 axis, has garnered significant attention due to its effectiveness in other malignancies, and recent studies have sought to extend these benefits to peritoneal mesothelioma. Atezolizumab, a PD-L1 inhibitor, has been evaluated in combination with bevacizumab, an anti-VEGF agent, as a second-line therapy for patients with peritoneal mesothelioma. In this setting, the combination therapy demonstrated a 1-year overall survival rate of 85% and a median response duration of 12.8 months [<a href="#b45-amjcaserep-26-e946585" class="usa-link" aria-describedby="b45-amjcaserep-26-e946585">45</a>]. This regimen appears particularly promising given the typically poor prognosis associated with peritoneal mesothelioma and the limited efficacy of existing therapies.</p>
<p>Avelumab, another PD-L1 inhibitor, has also shown potential as a second-line treatment. Notably, its efficacy appears to be enhanced in tumors that express PD-L1, with these patients exhibiting a higher response rate compared to those without PD-L1 expression [<a href="#b46-amjcaserep-26-e946585" class="usa-link" aria-describedby="b46-amjcaserep-26-e946585">46</a>]. This finding underscores the importance of biomarker-driven therapy in optimizing treatment outcomes for peritoneal mesothelioma.</p>
<p>In addition to PD-1/PD-L1 inhibitors, CTLA-4 inhibitors such as ipilimumab have been investigated for their therapeutic potential. Ipilimumab has been studied both as a monotherapy and in combination with other ICIs such as nivolumab. These combination regimens have shown significant clinical benefit, with median overall survival ranging from 10.2 to 19 months and a 1-year survival rate of 68% [<a href="#b47-amjcaserep-26-e946585" class="usa-link" aria-describedby="b47-amjcaserep-26-e946585">47</a>,<a href="#b48-amjcaserep-26-e946585" class="usa-link" aria-describedby="b48-amjcaserep-26-e946585">48</a>]. The combination of ipilimumab and nivolumab, in particular, is a synergistic approach that enhances the anti-tumor immune response, offering hope for improved outcomes in this challenging malignancy.</p>
<p>Despite these encouraging results, the limited data available on the use of ICIs in peritoneal mesothelioma preclude their widespread adoption as first-line therapies. Current evidence has not conclusively demonstrated that ICIs alone or in combination are superior to traditional chemotherapy in the initial treatment setting. However, the U.S. Food and Drug Administration (FDA) approved the combination of the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab for unresectable pleural mesothelioma in 2020, suggesting a potential future role for similar strategies in peritoneal mesothelioma.</p>
<p>This approval for pleural mesothelioma may pave the way for broader applications in peritoneal mesothelioma, particularly as more data become available. Ongoing clinical trials and expanded studies are crucial to determining the optimal use of ICIs in this context and may eventually establish these therapies as a standard part of the treatment arsenal against peritoneal mesothelioma.</p></section><section id="sec15"><h3 class="pmc_sec_title">Immune-Related Adverse Events (irAEs) and Fertility Considerations in Immunotherapy</h3>
<p>While ICIs have revolutionized the treatment landscape for various malignancies, the potential for irAEs remains a significant concern that must be carefully managed [<a href="#b49-amjcaserep-26-e946585" class="usa-link" aria-describedby="b49-amjcaserep-26-e946585">49</a>,<a href="#b50-amjcaserep-26-e946585" class="usa-link" aria-describedby="b50-amjcaserep-26-e946585">50</a>]. irAEs arise from the immune system’s hyperactivation, leading to off-target effects that can impact multiple organ systems. The incidence and severity of irAEs vary, with dermatologic toxicities such as pruritus and rash being among the most common manifestations [<a href="#b51-amjcaserep-26-e946585" class="usa-link" aria-describedby="b51-amjcaserep-26-e946585">51</a>].</p>
<p>Other common manifestations include lower digestive tract issues [<a href="#b52-amjcaserep-26-e946585" class="usa-link" aria-describedby="b52-amjcaserep-26-e946585">52</a>,<a href="#b53-amjcaserep-26-e946585" class="usa-link" aria-describedby="b53-amjcaserep-26-e946585">53</a>] (eg, diarrhea, colitis), hepatotoxicity [<a href="#b54-amjcaserep-26-e946585" class="usa-link" aria-describedby="b54-amjcaserep-26-e946585">54</a>] and endocrinopathies [<a href="#b55-amjcaserep-26-e946585" class="usa-link" aria-describedby="b55-amjcaserep-26-e946585">55</a>,<a href="#b56-amjcaserep-26-e946585" class="usa-link" aria-describedby="b56-amjcaserep-26-e946585">56</a>] (eg, hypophysitis, thyroid dysfunction). Despite the clinical effectiveness of treatment, irAEs cannot be ignored. The impact of irAEs is broad, affecting various organ systems through immunological enhancement and suppression. One of the most common irAEs is dermatologic toxicity, such as pruritus and rash [<a href="#b51-amjcaserep-26-e946585" class="usa-link" aria-describedby="b51-amjcaserep-26-e946585">51</a>].</p>
<p>The cardiovascular system can also be affected by irAEs, but these events are less common than dermatologic or gastrointestinal manifestations. Cardiotoxicity associated with ICIs may present as myocarditis, pericarditis, or even arrhythmias, and while rare, these conditions can be severe and potentially life-threatening. Cardiovascular irAEs require prompt recognition and management, often necessitating discontinuation of ICIs and initiation of immunosuppressive therapy [<a href="#b57-amjcaserep-26-e946585" class="usa-link" aria-describedby="b57-amjcaserep-26-e946585">57</a>,<a href="#b58-amjcaserep-26-e946585" class="usa-link" aria-describedby="b58-amjcaserep-26-e946585">58</a>].</p>
<p>Renal toxicity is another important irAE that clinicians must monitor for. Nephritis induced by ICIs can lead to acute kidney injury, which may necessitate cessation of therapy and the use of corticosteroids or other immunosuppressants to mitigate damage [<a href="#b59-amjcaserep-26-e946585" class="usa-link" aria-describedby="b59-amjcaserep-26-e946585">59</a>]. The renal system’s vulnerability to irAEs underscores the need for regular monitoring of renal function throughout the course of ICI therapy.</p>
<p>Pulmonary toxicity, including pneumonitis, is a well-documented irAE and can range from mild interstitial changes to severe, life-threatening inflammation requiring hospitalization. Patients presenting with respiratory symptoms such as cough, dyspnea, or chest pain during ICI therapy should be promptly evaluated for pneumonitis, with imaging studies and pulmonary function tests as necessary. The management of pneumonitis often involves corticosteroids and discontinuation of ICIs, with the decision to resume therapy carefully weighed against the risks of recurrence [<a href="#b60-amjcaserep-26-e946585" class="usa-link" aria-describedby="b60-amjcaserep-26-e946585">60</a>,<a href="#b61-amjcaserep-26-e946585" class="usa-link" aria-describedby="b61-amjcaserep-26-e946585">61</a>].</p>
<p>In the context of endocrinopathies, irAEs can lead to a wide spectrum of dysfunctions involving the pituitary, thyroid, adrenal glands, and pancreas. Hypophysitis, a common endocrine-related irAE, may present with symptoms of headache, fatigue, and visual disturbances and can result in secondary adrenal insufficiency [<a href="#b62-amjcaserep-26-e946585" class="usa-link" aria-describedby="b62-amjcaserep-26-e946585">62</a>]. Thyroid dysfunction, including hypothyroidism and hyperthyroidism, is frequently observed and may necessitate lifelong thyroid hormone replacement therapy [<a href="#b63-amjcaserep-26-e946585" class="usa-link" aria-describedby="b63-amjcaserep-26-e946585">63</a>]. Furthermore, adrenalitis can manifest as adrenal insufficiency, requiring prompt glucocorticoid replacement. The impact of these endocrine irAEs can be profound, affecting the patient’s quality of life and requiring ongoing management even after discontinuation of ICIs [<a href="#b64-amjcaserep-26-e946585" class="usa-link" aria-describedby="b64-amjcaserep-26-e946585">64</a>].</p>
<p>The reproductive system is not immune to the effects of irAEs. While data on the direct impact of ICIs on fertility are still emerging, there is growing concern about potential gonadal toxicity, particularly in women of childbearing age. Fertility preservation strategies, including sperm banking for men and oocyte or embryo cryopreservation for women, are recommended before initiating ICI therapy in patients with reproductive concerns. These proactive measures can help mitigate the potential long-term consequences of treatment on fertility [<a href="#b65-amjcaserep-26-e946585" class="usa-link" aria-describedby="b65-amjcaserep-26-e946585">65</a>].</p>
<p>For pregnant patients or those planning pregnancy, the use of ICIs poses unique challenges. Given the crucial role of the immune system in maintaining fetomaternal tolerance, the administration of ICIs during pregnancy raises concerns about the potential for immune-mediated pregnancy complications such as spontaneous abortion, preterm labor, or fetal growth restriction. Recently, human studies have shown that ICI use during pregnancy may be better tolerated than previously suspected [<a href="#b66-amjcaserep-26-e946585" class="usa-link" aria-describedby="b66-amjcaserep-26-e946585">66</a>].</p>
<p>In clinical practice, the decision to use ICIs in pregnant patients must be made on a case-by-case basis, with a thorough assessment of the risks and benefits. For women undergoing ICI therapy who are considering pregnancy, it is generally advised to delay conception until at least 6 months after the completion of treatment to allow for resolution of irAEs and stabilization of the immune system [<a href="#b67-amjcaserep-26-e946585" class="usa-link" aria-describedby="b67-amjcaserep-26-e946585">67</a>]. This precaution helps to minimize potential risks to both the mother and the fetus. Additionally, healthcare providers should engage in discussions with patients about fertility preservation options before starting ICI therapy, especially in younger patients who may wish to have children in the future.</p></section></section><section id="sec16"><h2 class="pmc_sec_title">Conclusions</h2>
<p>This report presents the case of a 44-year-old nulliparous woman diagnosed with low-grade epithelioid MPM, discovered incidentally during a laparotomic myomectomy. Initial imaging and histopathological assessments confirmed the diagnosis, with immunohistochemistry revealing positivity for calretinin and BAP1. Despite the recommendation for debulking surgery and HIPEC, the patient opted for fertility preservation, influencing her treatment decisions. Following chemotherapy and immunotherapy, the patient delivered a premature female baby with healthy outcome. This review illustrates the delicate balance between managing a serious cancer diagnosis and preserving fertility. It highlights the importance of personalized treatment plans, especially when patients face challenging decisions that impact both their health and future family plans. The successful outcome in this case, with the patient delivering a healthy baby, underscores the potential for favorable results of immunotherapy even in complex situations.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors thank the patient for approving the publication of her case.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn12"><p>Publisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher</p></div>
<div class="fn p" id="fn13">
<p>
<strong>Statement</strong>
</p>
<p>We affirm that informed consent was obtained from all participants involved in this case report.</p>
</div>
<div class="fn p" id="fn14">
<p>
<strong>Declaration of Figures’ Authenticity</strong>
</p>
<p>All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.</p>
</div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References:</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="b1-amjcaserep-26-e946585">
<span class="label">1.</span><cite>Sousa B, Silva J, Monteiro N, et al.  Malignant peritoneal mesothelioma: A case report. Cureus. 2023;15(8):e42902. doi: 10.7759/cureus.42902.</cite> [<a href="https://doi.org/10.7759/cureus.42902" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10474876/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37664365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cureus&amp;title=Malignant%20peritoneal%20mesothelioma:%20A%20case%20report&amp;author=B%20Sousa&amp;author=J%20Silva&amp;author=N%20Monteiro&amp;volume=15&amp;issue=8&amp;publication_year=2023&amp;pages=e42902&amp;pmid=37664365&amp;doi=10.7759/cureus.42902&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b2-amjcaserep-26-e946585">
<span class="label">2.</span><cite>Levy M, Boublikova L, Buchler T, Simsa J. Treatment of malignant peritoneal mesothelioma. Klin Onkol. 2019;32(5):333–37. doi: 10.14735/amko2019333.</cite> [<a href="https://doi.org/10.14735/amko2019333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31610664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Klin%20Onkol&amp;title=Treatment%20of%20malignant%20peritoneal%20mesothelioma&amp;author=M%20Levy&amp;author=L%20Boublikova&amp;author=T%20Buchler&amp;author=J%20Simsa&amp;volume=32&amp;issue=5&amp;publication_year=2019&amp;pages=333-37&amp;pmid=31610664&amp;doi=10.14735/amko2019333&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b3-amjcaserep-26-e946585">
<span class="label">3.</span><cite>Pandav V, Patel J, Inampudi JV, et al.  Incidence of additional primary malignancies in patients with malignant peritoneal mesothelioma. J Clin Oncol. 2023;41(16 Suppl.):e20535–e35.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Incidence%20of%20additional%20primary%20malignancies%20in%20patients%20with%20malignant%20peritoneal%20mesothelioma&amp;author=V%20Pandav&amp;author=J%20Patel&amp;author=JV%20Inampudi&amp;volume=41&amp;issue=16%20Suppl.&amp;publication_year=2023&amp;pages=e20535-e35&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b4-amjcaserep-26-e946585">
<span class="label">4.</span><cite>van Kooten JP, Belderbos RA, von der Thusen JH, et al.  Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: A population-based study. Thorax. 2022;77(12):1260–67. doi: 10.1136/thoraxjnl-2021-217709.</cite> [<a href="https://doi.org/10.1136/thoraxjnl-2021-217709" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9685713/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35149582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thorax&amp;title=Incidence,%20treatment%20and%20survival%20of%20malignant%20pleural%20and%20peritoneal%20mesothelioma:%20A%20population-based%20study&amp;author=JP%20van%20Kooten&amp;author=RA%20Belderbos&amp;author=JH%20von%20der%20Thusen&amp;volume=77&amp;issue=12&amp;publication_year=2022&amp;pages=1260-67&amp;pmid=35149582&amp;doi=10.1136/thoraxjnl-2021-217709&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b5-amjcaserep-26-e946585">
<span class="label">5.</span><cite>Idkedek M, Tahayneh KS, Abu-Akar F, Bakri IA. Case report and review of literature: familial malignant pleural mesothelioma in a 39 years old patient with an inconclusive (18)F-FDG PET/CT result. Front Surg. 2022;9:819596. doi: 10.3389/fsurg.2022.819596.</cite> [<a href="https://doi.org/10.3389/fsurg.2022.819596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8963911/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35360426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Surg&amp;title=Case%20report%20and%20review%20of%20literature:%20familial%20malignant%20pleural%20mesothelioma%20in%20a%2039%20years%20old%20patient%20with%20an%20inconclusive%20(18)F-FDG%20PET/CT%20result&amp;author=M%20Idkedek&amp;author=KS%20Tahayneh&amp;author=F%20Abu-Akar&amp;author=IA%20Bakri&amp;volume=9&amp;publication_year=2022&amp;pages=819596&amp;pmid=35360426&amp;doi=10.3389/fsurg.2022.819596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b6-amjcaserep-26-e946585">
<span class="label">6.</span><cite>Zhao F, Zhang YL, Liu X, et al.  [A case of malignant peritoneal mesothelioma.] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2023;41(4):307–9. doi: 10.3760/cma.j.cn121094-20220328-00158. [in Chinese]</cite> [<a href="https://doi.org/10.3760/cma.j.cn121094-20220328-00158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37248188/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Zhonghua%20Lao%20Dong%20Wei%20Sheng%20Zhi%20Ye%20Bing%20Za%20Zhi&amp;title=%5BA%20case%20of%20malignant%20peritoneal%20mesothelioma.%5D&amp;author=F%20Zhao&amp;author=YL%20Zhang&amp;author=X%20Liu&amp;volume=41&amp;issue=4&amp;publication_year=2023&amp;pages=307-9&amp;pmid=37248188&amp;doi=10.3760/cma.j.cn121094-20220328-00158&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b7-amjcaserep-26-e946585">
<span class="label">7.</span><cite>Marques de Sousa S, Pereira F, Duarte M, et al.  Malignant peritoneal mesothelioma as a rare cause of dyspeptic complaints and ascites: A diagnostic challenge. GE Port J Gastroenterol. 2020;27(3):197–202. doi: 10.1159/000503075.</cite> [<a href="https://doi.org/10.1159/000503075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7250362/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32509926/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=GE%20Port%20J%20Gastroenterol&amp;title=Malignant%20peritoneal%20mesothelioma%20as%20a%20rare%20cause%20of%20dyspeptic%20complaints%20and%20ascites:%20A%20diagnostic%20challenge&amp;author=S%20Marques%20de%20Sousa&amp;author=F%20Pereira&amp;author=M%20Duarte&amp;volume=27&amp;issue=3&amp;publication_year=2020&amp;pages=197-202&amp;pmid=32509926&amp;doi=10.1159/000503075&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b8-amjcaserep-26-e946585">
<span class="label">8.</span><cite>Salo SAS, Ilonen I, Laaksonen S, et al.  Malignant peritoneal mesothelioma: Treatment options and survival. Anticancer Res. 2019;39(2):839–45. doi: 10.21873/anticanres.13183.</cite> [<a href="https://doi.org/10.21873/anticanres.13183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30711965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res&amp;title=Malignant%20peritoneal%20mesothelioma:%20Treatment%20options%20and%20survival&amp;author=SAS%20Salo&amp;author=I%20Ilonen&amp;author=S%20Laaksonen&amp;volume=39&amp;issue=2&amp;publication_year=2019&amp;pages=839-45&amp;pmid=30711965&amp;doi=10.21873/anticanres.13183&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b9-amjcaserep-26-e946585">
<span class="label">9.</span><cite>de Boer NL, van Kooten JP, Burger JWA, et al.  Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open. 2019;9(5):e026779. doi: 10.1136/bmjopen-2018-026779.</cite> [<a href="https://doi.org/10.1136/bmjopen-2018-026779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6530331/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31092657/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20Open&amp;title=Adjuvant%20dendritic%20cell%20based%20immunotherapy%20(DCBI)%20after%20cytoreductive%20surgery%20(CRS)%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20(HIPEC)%20for%20peritoneal%20mesothelioma,%20a%20phase%20II%20single%20centre%20open-label%20clinical%20trial:%20rationale%20and%20design%20of%20the%20MESOPEC%20trial&amp;author=NL%20de%20Boer&amp;author=JP%20van%20Kooten&amp;author=JWA%20Burger&amp;volume=9&amp;issue=5&amp;publication_year=2019&amp;pages=e026779&amp;pmid=31092657&amp;doi=10.1136/bmjopen-2018-026779&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b10-amjcaserep-26-e946585">
<span class="label">10.</span><cite>Mezei G, Chang ET, Mowat FS, Moolgavkar SH. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis. Ann Epidemiol. 2017;27(5):348–59.e11. doi: 10.1016/j.annepidem.2017.04.001.</cite> [<a href="https://doi.org/10.1016/j.annepidem.2017.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28527639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Epidemiol&amp;title=Epidemiology%20of%20mesothelioma%20of%20the%20pericardium%20and%20tunica%20vaginalis%20testis&amp;author=G%20Mezei&amp;author=ET%20Chang&amp;author=FS%20Mowat&amp;author=SH%20Moolgavkar&amp;volume=27&amp;issue=5&amp;publication_year=2017&amp;pages=348-59.e11&amp;pmid=28527639&amp;doi=10.1016/j.annepidem.2017.04.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b11-amjcaserep-26-e946585">
<span class="label">11.</span><cite>Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: A review. Ann Transl Med. 2017;5(11):236. doi: 10.21037/atm.2017.03.96.</cite> [<a href="https://doi.org/10.21037/atm.2017.03.96" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5497105/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28706904/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Transl%20Med&amp;title=Malignant%20peritoneal%20mesothelioma:%20A%20review&amp;author=J%20Kim&amp;author=S%20Bhagwandin&amp;author=DM%20Labow&amp;volume=5&amp;issue=11&amp;publication_year=2017&amp;pages=236&amp;pmid=28706904&amp;doi=10.21037/atm.2017.03.96&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b12-amjcaserep-26-e946585">
<span class="label">12.</span><cite>Zhao Z, Li J, Tan F, et al.  Assessing the global burden of mesothelioma: Trends, socioeconomic influences, and asbestos exposure: A retrospective cohort study. Int J Surg. 2024 doi: 10.1097/JS9.0000000000001900. [Online ahead of print]</cite> [<a href="https://doi.org/10.1097/JS9.0000000000001900" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11745607/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38954660/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Surg.&amp;title=Assessing%20the%20global%20burden%20of%20mesothelioma:%20Trends,%20socioeconomic%20influences,%20and%20asbestos%20exposure:%20A%20retrospective%20cohort%20study.&amp;author=Z%20Zhao&amp;author=J%20Li&amp;author=F%20Tan&amp;publication_year=2024&amp;pmid=38954660&amp;doi=10.1097/JS9.0000000000001900&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b13-amjcaserep-26-e946585">
<span class="label">13.</span><cite>Boffetta P. Epidemiology of peritoneal mesothelioma: A review. Ann Oncol. 2007;18(6):985–90. doi: 10.1093/annonc/mdl345.</cite> [<a href="https://doi.org/10.1093/annonc/mdl345" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17030547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Epidemiology%20of%20peritoneal%20mesothelioma:%20A%20review&amp;author=P%20Boffetta&amp;volume=18&amp;issue=6&amp;publication_year=2007&amp;pages=985-90&amp;pmid=17030547&amp;doi=10.1093/annonc/mdl345&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b14-amjcaserep-26-e946585">
<span class="label">14.</span><cite>Husain AN, Chapel DB, Attanoos R, et al.  Guidelines for pathologic diagnosis of mesothelioma: 2023 Update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251–71. doi: 10.5858/arpa.2023-0304-RA.</cite> [<a href="https://doi.org/10.5858/arpa.2023-0304-RA" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38586983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Pathol%20Lab%20Med&amp;title=Guidelines%20for%20pathologic%20diagnosis%20of%20mesothelioma:%202023%20Update%20of%20the%20consensus%20statement%20from%20the%20International%20Mesothelioma%20Interest%20Group&amp;author=AN%20Husain&amp;author=DB%20Chapel&amp;author=R%20Attanoos&amp;volume=148&amp;issue=11&amp;publication_year=2024&amp;pages=1251-71&amp;pmid=38586983&amp;doi=10.5858/arpa.2023-0304-RA&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b15-amjcaserep-26-e946585">
<span class="label">15.</span><cite>Napolitano A, Pellegrini L, Dey A, et al.  Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene. 2016;35(15):1996–2002. doi: 10.1038/onc.2015.243.</cite> [<a href="https://doi.org/10.1038/onc.2015.243" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5018040/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26119930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Minimal%20asbestos%20exposure%20in%20germline%20BAP1%20heterozygous%20mice%20is%20associated%20with%20deregulated%20inflammatory%20response%20and%20increased%20risk%20of%20mesothelioma&amp;author=A%20Napolitano&amp;author=L%20Pellegrini&amp;author=A%20Dey&amp;volume=35&amp;issue=15&amp;publication_year=2016&amp;pages=1996-2002&amp;pmid=26119930&amp;doi=10.1038/onc.2015.243&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b16-amjcaserep-26-e946585">
<span class="label">16.</span><cite>Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366(9483):397–408. doi: 10.1016/S0140-6736(05)67025-0.</cite> [<a href="https://doi.org/10.1016/S0140-6736(05)67025-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16054941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Malignant%20mesothelioma&amp;author=BW%20Robinson&amp;author=AW%20Musk&amp;author=RA%20Lake&amp;volume=366&amp;issue=9483&amp;publication_year=2005&amp;pages=397-408&amp;pmid=16054941&amp;doi=10.1016/S0140-6736(05)67025-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b17-amjcaserep-26-e946585">
<span class="label">17.</span><cite>Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89(3):269–73. doi: 10.1177/030089160308900307.</cite> [<a href="https://doi.org/10.1177/030089160308900307" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12908781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tumori&amp;title=Clinical%20presentation%20of%20peritoneal%20mesothelioma&amp;author=YI%20Acherman&amp;author=LS%20Welch&amp;author=CM%20Bromley&amp;author=PH%20Sugarbaker&amp;volume=89&amp;issue=3&amp;publication_year=2003&amp;pages=269-73&amp;pmid=12908781&amp;doi=10.1177/030089160308900307&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b18-amjcaserep-26-e946585">
<span class="label">18.</span><cite>Sugarbaker PH, Yan H, Grazi RV, Shmookler BM. Early localized peritoneal mesothelioma as an incidental finding at laparoscopy. Report of a case and implications regarding natural history of the disease. Cancer. 2000;89(6):1279–84. doi: 10.1002/1097-0142(20000915)89:6&lt;1279::aid-cncr12&gt;3.0.co;2-8.</cite> [<a href="https://doi.org/10.1002/1097-0142(20000915)89:6&lt;1279::aid-cncr12&gt;3.0.co;2-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11002223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Early%20localized%20peritoneal%20mesothelioma%20as%20an%20incidental%20finding%20at%20laparoscopy.%20Report%20of%20a%20case%20and%20implications%20regarding%20natural%20history%20of%20the%20disease&amp;author=PH%20Sugarbaker&amp;author=H%20Yan&amp;author=RV%20Grazi&amp;author=BM%20Shmookler&amp;volume=89&amp;issue=6&amp;publication_year=2000&amp;pages=1279-84&amp;pmid=11002223&amp;doi=10.1002/1097-0142(20000915)89:6&lt;1279::aid-cncr12&gt;3.0.co;2-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b19-amjcaserep-26-e946585">
<span class="label">19.</span><cite>Kato K, Gemba K, Fujimoto N, et al.  Computed tomographic features of malignant peritoneal mesothelioma. Anticancer Res. 2016;36(3):1067–72.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/26976999/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res&amp;title=Computed%20tomographic%20features%20of%20malignant%20peritoneal%20mesothelioma&amp;author=K%20Kato&amp;author=K%20Gemba&amp;author=N%20Fujimoto&amp;volume=36&amp;issue=3&amp;publication_year=2016&amp;pages=1067-72&amp;pmid=26976999&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b20-amjcaserep-26-e946585">
<span class="label">20.</span><cite>Carbone M, Shimizu D, Napolitano A, et al.  Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget. 2016;7(37):59314–21. doi: 10.18632/oncotarget.10653.</cite> [<a href="https://doi.org/10.18632/oncotarget.10653" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5312314/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27447750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Positive%20nuclear%20BAP1%20immunostaining%20helps%20differentiate%20non-small%20cell%20lung%20carcinomas%20from%20malignant%20mesothelioma&amp;author=M%20Carbone&amp;author=D%20Shimizu&amp;author=A%20Napolitano&amp;volume=7&amp;issue=37&amp;publication_year=2016&amp;pages=59314-21&amp;pmid=27447750&amp;doi=10.18632/oncotarget.10653&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b21-amjcaserep-26-e946585">
<span class="label">21.</span><cite>Kwon J, Lee D, Lee S-A. BAP1 as a guardian of genome stability: Implications in human cancer. Exp Mol Med. 2023;55(4):745–54. doi: 10.1038/s12276-023-00979-1.</cite> [<a href="https://doi.org/10.1038/s12276-023-00979-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10167335/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37009801/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Mol%20Med&amp;title=BAP1%20as%20a%20guardian%20of%20genome%20stability:%20Implications%20in%20human%20cancer&amp;author=J%20Kwon&amp;author=D%20Lee&amp;author=S-A%20Lee&amp;volume=55&amp;issue=4&amp;publication_year=2023&amp;pages=745-54&amp;pmid=37009801&amp;doi=10.1038/s12276-023-00979-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b22-amjcaserep-26-e946585">
<span class="label">22.</span><cite>Rossi G, Righi L, Barbisan F, et al.  BAP1 loss, nuclear grading, and nonepithelioid features in the diagnosis of mesothelioma in Italy: Nevermore without the pathology report. J Pers Med. 2024;14(4):394. doi: 10.3390/jpm14040394.</cite> [<a href="https://doi.org/10.3390/jpm14040394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11051266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38673021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pers%20Med&amp;title=BAP1%20loss,%20nuclear%20grading,%20and%20nonepithelioid%20features%20in%20the%20diagnosis%20of%20mesothelioma%20in%20Italy:%20Nevermore%20without%20the%20pathology%20report&amp;author=G%20Rossi&amp;author=L%20Righi&amp;author=F%20Barbisan&amp;volume=14&amp;issue=4&amp;publication_year=2024&amp;pages=394&amp;pmid=38673021&amp;doi=10.3390/jpm14040394&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b23-amjcaserep-26-e946585">
<span class="label">23.</span><cite>Carbone M, Minaai M, Takinishi Y, et al.  Preventive and therapeutic opportunities: Targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma. J Transl Med. 2023;21(1):749. doi: 10.1186/s12967-023-04614-5.</cite> [<a href="https://doi.org/10.1186/s12967-023-04614-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10599047/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37880686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Transl%20Med&amp;title=Preventive%20and%20therapeutic%20opportunities:%20Targeting%20BAP1%20and/or%20HMGB1%20pathways%20to%20diminish%20the%20burden%20of%20mesothelioma&amp;author=M%20Carbone&amp;author=M%20Minaai&amp;author=Y%20Takinishi&amp;volume=21&amp;issue=1&amp;publication_year=2023&amp;pages=749&amp;pmid=37880686&amp;doi=10.1186/s12967-023-04614-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b24-amjcaserep-26-e946585">
<span class="label">24.</span><cite>Ghafoor A, Mian I, Wagner C, et al.  Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in BAP1 gene. JTO Clin Res Rep. 2021;2(10):100231. doi: 10.1016/j.jtocrr.2021.100231.</cite> [<a href="https://doi.org/10.1016/j.jtocrr.2021.100231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8502774/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34661178/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JTO%20Clin%20Res%20Rep&amp;title=Phase%202%20study%20of%20olaparib%20in%20malignant%20mesothelioma%20and%20correlation%20of%20efficacy%20with%20germline%20or%20somatic%20mutations%20in%20BAP1%20gene&amp;author=A%20Ghafoor&amp;author=I%20Mian&amp;author=C%20Wagner&amp;volume=2&amp;issue=10&amp;publication_year=2021&amp;pages=100231&amp;pmid=34661178&amp;doi=10.1016/j.jtocrr.2021.100231&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b25-amjcaserep-26-e946585">
<span class="label">25.</span><cite>Calabrò L, Bronte G, Grosso F, et al.  Immunotherapy of mesothelioma: The evolving change of a long-standing therapeutic dream. Front Immunol. 2023;14:1333661. doi: 10.3389/fimmu.2023.1333661.</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1333661" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10800748/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38259475/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=Immunotherapy%20of%20mesothelioma:%20The%20evolving%20change%20of%20a%20long-standing%20therapeutic%20dream&amp;author=L%20Calabr%C3%B2&amp;author=G%20Bronte&amp;author=F%20Grosso&amp;volume=14&amp;publication_year=2023&amp;pages=1333661&amp;pmid=38259475&amp;doi=10.3389/fimmu.2023.1333661&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b26-amjcaserep-26-e946585">
<span class="label">26.</span><cite>Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: A review. Transl Lung Cancer Res. 2018;7(5):537–42. doi: 10.21037/tlcr.2018.10.04.</cite> [<a href="https://doi.org/10.21037/tlcr.2018.10.04" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6204422/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30450291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Lung%20Cancer%20Res&amp;title=Malignant%20peritoneal%20mesothelioma:%20A%20review&amp;author=G%20Broeckx&amp;author=P%20Pauwels&amp;volume=7&amp;issue=5&amp;publication_year=2018&amp;pages=537-42&amp;pmid=30450291&amp;doi=10.21037/tlcr.2018.10.04&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b27-amjcaserep-26-e946585">
<span class="label">27.</span><cite>Kusamura S, Baratti D, De Simone M, et al.  Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers (Basel) 2023;15(3):662. doi: 10.3390/cancers15030662.</cite> [<a href="https://doi.org/10.3390/cancers15030662" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9913096/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36765620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Diagnostic%20and%20therapeutic%20pathway%20in%20diffuse%20malignant%20peritoneal%20mesothelioma&amp;author=S%20Kusamura&amp;author=D%20Baratti&amp;author=M%20De%20Simone&amp;volume=15&amp;issue=3&amp;publication_year=2023&amp;pages=662&amp;pmid=36765620&amp;doi=10.3390/cancers15030662&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b28-amjcaserep-26-e946585">
<span class="label">28.</span><cite>Feldman AL, Libutti SK, Pingpank JF, et al.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–67. doi: 10.1200/JCO.2003.04.150.</cite> [<a href="https://doi.org/10.1200/JCO.2003.04.150" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14673042/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Analysis%20of%20factors%20associated%20with%20outcome%20in%20patients%20with%20malignant%20peritoneal%20mesothelioma%20undergoing%20surgical%20debulking%20and%20intraperitoneal%20chemotherapy&amp;author=AL%20Feldman&amp;author=SK%20Libutti&amp;author=JF%20Pingpank&amp;volume=21&amp;issue=24&amp;publication_year=2003&amp;pages=4560-67&amp;pmid=14673042&amp;doi=10.1200/JCO.2003.04.150&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b29-amjcaserep-26-e946585">
<span class="label">29.</span><cite>Yan TD, Brun EA, Cerruto CA, et al.  Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14(1):41–49. doi: 10.1245/s10434-006-9169-7.</cite> [<a href="https://doi.org/10.1245/s10434-006-9169-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17039392/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=Prognostic%20indicators%20for%20patients%20undergoing%20cytoreductive%20surgery%20and%20perioperative%20intraperitoneal%20chemotherapy%20for%20diffuse%20malignant%20peritoneal%20mesothelioma&amp;author=TD%20Yan&amp;author=EA%20Brun&amp;author=CA%20Cerruto&amp;volume=14&amp;issue=1&amp;publication_year=2007&amp;pages=41-49&amp;pmid=17039392&amp;doi=10.1245/s10434-006-9169-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b30-amjcaserep-26-e946585">
<span class="label">30.</span><cite>Yan TD, Deraco M, Baratti D, et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42. doi: 10.1200/JCO.2009.23.9640.</cite> [<a href="https://doi.org/10.1200/JCO.2009.23.9640" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19917862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Cytoreductive%20surgery%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20for%20malignant%20peritoneal%20mesothelioma:%20Multi-institutional%20experience&amp;author=TD%20Yan&amp;author=M%20Deraco&amp;author=D%20Baratti&amp;volume=27&amp;issue=36&amp;publication_year=2009&amp;pages=6237-42&amp;pmid=19917862&amp;doi=10.1200/JCO.2009.23.9640&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b31-amjcaserep-26-e946585">
<span class="label">31.</span><cite>Baratti D, Kusamura S, Cabras AD, et al.  Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) Eur J Cancer. 2013;49(15):3140–48. doi: 10.1016/j.ejca.2013.05.027.</cite> [<a href="https://doi.org/10.1016/j.ejca.2013.05.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23831335/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Diffuse%20malignant%20peritoneal%20mesothelioma:%20long-term%20survival%20with%20complete%20cytoreductive%20surgery%20followed%20by%20hyperthermic%20intraperitoneal%20chemotherapy%20(HIPEC)&amp;author=D%20Baratti&amp;author=S%20Kusamura&amp;author=AD%20Cabras&amp;volume=49&amp;issue=15&amp;publication_year=2013&amp;pages=3140-48&amp;pmid=23831335&amp;doi=10.1016/j.ejca.2013.05.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b32-amjcaserep-26-e946585">
<span class="label">32.</span><cite>Acs M, Gerken M, Gajic I, et al.  Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Langenbecks Arch Surg. 2022;407(7):3057–67. doi: 10.1007/s00423-022-02594-6.</cite> [<a href="https://doi.org/10.1007/s00423-022-02594-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35732846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Langenbecks%20Arch%20Surg&amp;title=Ten-year%20single-center%20experience%20with%20treatment%20of%20primary%20diffuse%20malignant%20peritoneal%20mesothelioma%20(DMPM)%20by%20cytoreductive%20surgery%20(CRS)%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20(HIPEC)&amp;author=M%20Acs&amp;author=M%20Gerken&amp;author=I%20Gajic&amp;volume=407&amp;issue=7&amp;publication_year=2022&amp;pages=3057-67&amp;pmid=35732846&amp;doi=10.1007/s00423-022-02594-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b33-amjcaserep-26-e946585">
<span class="label">33.</span><cite>Helm JH, Miura JT, Glenn JA, et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: A systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93. doi: 10.1245/s10434-014-3978-x.</cite> [<a href="https://doi.org/10.1245/s10434-014-3978-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25124472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=Cytoreductive%20surgery%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20for%20malignant%20peritoneal%20mesothelioma:%20A%20systematic%20review%20and%20meta-analysis&amp;author=JH%20Helm&amp;author=JT%20Miura&amp;author=JA%20Glenn&amp;volume=22&amp;issue=5&amp;publication_year=2015&amp;pages=1686-93&amp;pmid=25124472&amp;doi=10.1245/s10434-014-3978-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b34-amjcaserep-26-e946585">
<span class="label">34.</span><cite>Santoro A, O’Brien ME, Stahel RA, et al.  Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756–63. doi: 10.1097/JTO.0b013e31817c73d6.</cite> [<a href="https://doi.org/10.1097/JTO.0b013e31817c73d6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18594322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Pemetrexed%20plus%20cisplatin%20or%20pemetrexed%20plus%20carboplatin%20for%20chemona%C3%AFve%20patients%20with%20malignant%20pleural%20mesothelioma:%20Results%20of%20the%20International%20Expanded%20Access%20Program&amp;author=A%20Santoro&amp;author=ME%20O%E2%80%99Brien&amp;author=RA%20Stahel&amp;volume=3&amp;issue=7&amp;publication_year=2008&amp;pages=756-63&amp;pmid=18594322&amp;doi=10.1097/JTO.0b013e31817c73d6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b35-amjcaserep-26-e946585">
<span class="label">35.</span><cite>Jänne PA, Wozniak AJ, Belani CP, et al.  Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1(6):506–12.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/17409909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Pemetrexed%20alone%20or%20in%20combination%20with%20cisplatin%20in%20previously%20treated%20malignant%20pleural%20mesothelioma:%20Outcomes%20from%20a%20phase%20IIIB%20expanded%20access%20program&amp;author=PA%20J%C3%A4nne&amp;author=AJ%20Wozniak&amp;author=CP%20Belani&amp;volume=1&amp;issue=6&amp;publication_year=2006&amp;pages=506-12&amp;pmid=17409909&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b36-amjcaserep-26-e946585">
<span class="label">36.</span><cite>Obasaju CK, Ye Z, Wozniak AJ, et al.  Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program. Lung Cancer. 2007;55(2):187–94. doi: 10.1016/j.lungcan.2006.09.023.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2006.09.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17092602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Single-arm,%20open%20label%20study%20of%20pemetrexed%20plus%20cisplatin%20in%20chemotherapy%20na%C3%AFve%20patients%20with%20malignant%20pleural%20mesothelioma:%20Outcomes%20of%20an%20expanded%20access%20program&amp;author=CK%20Obasaju&amp;author=Z%20Ye&amp;author=AJ%20Wozniak&amp;volume=55&amp;issue=2&amp;publication_year=2007&amp;pages=187-94&amp;pmid=17092602&amp;doi=10.1016/j.lungcan.2006.09.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b37-amjcaserep-26-e946585">
<span class="label">37.</span><cite>Yoshikawa Y, Kuribayashi K, Minami T, et al.  Epigenetic alterations and biomarkers for immune checkpoint inhibitors-current standards and future perspectives in malignant pleural mesothelioma treatment. Front Oncol. 2020;10:554570. doi: 10.3389/fonc.2020.554570.</cite> [<a href="https://doi.org/10.3389/fonc.2020.554570" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7767988/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33381446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Epigenetic%20alterations%20and%20biomarkers%20for%20immune%20checkpoint%20inhibitors-current%20standards%20and%20future%20perspectives%20in%20malignant%20pleural%20mesothelioma%20treatment&amp;author=Y%20Yoshikawa&amp;author=K%20Kuribayashi&amp;author=T%20Minami&amp;volume=10&amp;publication_year=2020&amp;pages=554570&amp;pmid=33381446&amp;doi=10.3389/fonc.2020.554570&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b38-amjcaserep-26-e946585">
<span class="label">38.</span><cite>Votanopoulos KI, Sugarbaker P, Deraco M, et al.  Is Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018;25(3):667–73. doi: 10.1245/s10434-017-6293-5.</cite> [<a href="https://doi.org/10.1245/s10434-017-6293-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29260418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Surg%20Oncol&amp;title=Is%20Cytoreductive%20surgery%20with%20hyperthermic%20intraperitoneal%20chemotherapy%20justified%20for%20biphasic%20variants%20of%20peritoneal%20mesothelioma?%20Outcomes%20from%20the%20Peritoneal%20Surface%20Oncology%20Group%20International%20Registry&amp;author=KI%20Votanopoulos&amp;author=P%20Sugarbaker&amp;author=M%20Deraco&amp;volume=25&amp;issue=3&amp;publication_year=2018&amp;pages=667-73&amp;pmid=29260418&amp;doi=10.1245/s10434-017-6293-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b39-amjcaserep-26-e946585">
<span class="label">39.</span><cite>Jänne PA, Wozniak AJ, Belani CP, et al.  Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40–46. doi: 10.3816/CLC.2005.n.020.</cite> [<a href="https://doi.org/10.3816/CLC.2005.n.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16098243/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lung%20Cancer&amp;title=Open-label%20study%20of%20pemetrexed%20alone%20or%20in%20combination%20with%20cisplatin%20for%20the%20treatment%20of%20patients%20with%20peritoneal%20mesothelioma:%20Outcomes%20of%20an%20expanded%20access%20program&amp;author=PA%20J%C3%A4nne&amp;author=AJ%20Wozniak&amp;author=CP%20Belani&amp;volume=7&amp;issue=1&amp;publication_year=2005&amp;pages=40-46&amp;pmid=16098243&amp;doi=10.3816/CLC.2005.n.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b40-amjcaserep-26-e946585">
<span class="label">40.</span><cite>Fujimoto E, Kijima T, Kuribayashi K, et al.  First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17(9):865–72. doi: 10.1080/14737140.2017.1340157.</cite> [<a href="https://doi.org/10.1080/14737140.2017.1340157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28594258/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Anticancer%20Ther&amp;title=First-line%20chemotherapy%20with%20pemetrexed%20plus%20cisplatin%20for%20malignant%20peritoneal%20mesothelioma&amp;author=E%20Fujimoto&amp;author=T%20Kijima&amp;author=K%20Kuribayashi&amp;volume=17&amp;issue=9&amp;publication_year=2017&amp;pages=865-72&amp;pmid=28594258&amp;doi=10.1080/14737140.2017.1340157&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b41-amjcaserep-26-e946585">
<span class="label">41.</span><cite>Nagata Y, Sawada R, Takashima A, et al.  Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol. 2019;49(11):1004–8. doi: 10.1093/jjco/hyz104.</cite> [<a href="https://doi.org/10.1093/jjco/hyz104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31287877/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jpn%20J%20Clin%20Oncol&amp;title=Efficacy%20and%20safety%20of%20pemetrexed%20plus%20cisplatin%20as%20first-line%20chemotherapy%20in%20advanced%20malignant%20peritoneal%20mesothelioma&amp;author=Y%20Nagata&amp;author=R%20Sawada&amp;author=A%20Takashima&amp;volume=49&amp;issue=11&amp;publication_year=2019&amp;pages=1004-8&amp;pmid=31287877&amp;doi=10.1093/jjco/hyz104&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b42-amjcaserep-26-e946585">
<span class="label">42.</span><cite>Carteni G, Manegold C, Garcia GM, et al.  Malignant peritoneal mesothelioma – results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64(2):211–18. doi: 10.1016/j.lungcan.2008.08.013.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2008.08.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19042053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Malignant%20peritoneal%20mesothelioma%20%E2%80%93%20results%20from%20the%20International%20Expanded%20Access%20Program%20using%20pemetrexed%20alone%20or%20in%20combination%20with%20a%20platinum%20agent&amp;author=G%20Carteni&amp;author=C%20Manegold&amp;author=GM%20Garcia&amp;volume=64&amp;issue=2&amp;publication_year=2009&amp;pages=211-18&amp;pmid=19042053&amp;doi=10.1016/j.lungcan.2008.08.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b43-amjcaserep-26-e946585">
<span class="label">43.</span><cite>Gribkova YV, Alexander HR. Management of patients with malignant peritoneal mesothelioma: The evolving role of surgery and immunotherapy. Medical Research Archives. 2022;10(11) 193546531.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Medical%20Research%20Archives&amp;title=Management%20of%20patients%20with%20malignant%20peritoneal%20mesothelioma:%20The%20evolving%20role%20of%20surgery%20and%20immunotherapy&amp;author=YV%20Gribkova&amp;author=HR%20Alexander&amp;volume=10&amp;issue=11&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b44-amjcaserep-26-e946585">
<span class="label">44.</span><cite>Zhou M, Joshi N, Raj KP, et al.  PD-1/PD-L1 checkpoint inhibitor immunotherapy for malignant pleural mesothelioma: Case series and literature review. Clin Lung Cancer. 2021;22(3):e329–e35. doi: 10.1016/j.cllc.2020.05.012.</cite> [<a href="https://doi.org/10.1016/j.cllc.2020.05.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32624413/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Lung%20Cancer&amp;title=PD-1/PD-L1%20checkpoint%20inhibitor%20immunotherapy%20for%20malignant%20pleural%20mesothelioma:%20Case%20series%20and%20literature%20review&amp;author=M%20Zhou&amp;author=N%20Joshi&amp;author=KP%20Raj&amp;volume=22&amp;issue=3&amp;publication_year=2021&amp;pages=e329-e35&amp;pmid=32624413&amp;doi=10.1016/j.cllc.2020.05.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b45-amjcaserep-26-e946585">
<span class="label">45.</span><cite>Raghav K, Liu S, Overman MJ, et al.  Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 2021;11(11):2738–47. doi: 10.1158/2159-8290.CD-21-0331.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-21-0331" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8563380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34261675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Efficacy,%20safety,%20and%20biomarker%20analysis%20of%20combined%20PD-L1%20(atezolizumab)%20and%20VEGF%20(bevacizumab)%20blockade%20in%20advanced%20malignant%20peritoneal%20mesothelioma&amp;author=K%20Raghav&amp;author=S%20Liu&amp;author=MJ%20Overman&amp;volume=11&amp;issue=11&amp;publication_year=2021&amp;pages=2738-47&amp;pmid=34261675&amp;doi=10.1158/2159-8290.CD-21-0331&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b46-amjcaserep-26-e946585">
<span class="label">46.</span><cite>Hassan R, Thomas A, Nemunaitis JJ, et al.  Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):351–57. doi: 10.1001/jamaoncol.2018.5428.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.5428" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6439847/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30605211/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Efficacy%20and%20safety%20of%20avelumab%20treatment%20in%20patients%20with%20advanced%20unresectable%20mesothelioma:%20Phase%201b%20results%20from%20the%20JAVELIN%20solid%20tumor%20trial&amp;author=R%20Hassan&amp;author=A%20Thomas&amp;author=JJ%20Nemunaitis&amp;volume=5&amp;issue=3&amp;publication_year=2019&amp;pages=351-57&amp;pmid=30605211&amp;doi=10.1001/jamaoncol.2018.5428&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b47-amjcaserep-26-e946585">
<span class="label">47.</span><cite>Raghav K, Liu S, Overman M, et al.  Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 2021;4(8):e2119934. doi: 10.1001/jamanetworkopen.2021.19934.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2021.19934" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8346939/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34357397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw%20Open&amp;title=Clinical%20efficacy%20of%20immune%20checkpoint%20inhibitors%20in%20patients%20with%20advanced%20malignant%20peritoneal%20mesothelioma&amp;author=K%20Raghav&amp;author=S%20Liu&amp;author=M%20Overman&amp;volume=4&amp;issue=8&amp;publication_year=2021&amp;pages=e2119934&amp;pmid=34357397&amp;doi=10.1001/jamanetworkopen.2021.19934&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b48-amjcaserep-26-e946585">
<span class="label">48.</span><cite>Fennell DA, Ewings S, Ottensmeier C, et al.  Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–40. doi: 10.1016/S1470-2045(21)00471-X.</cite> [<a href="https://doi.org/10.1016/S1470-2045(21)00471-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8560642/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34656227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Nivolumab%20versus%20placebo%20in%20patients%20with%20relapsed%20malignant%20mesothelioma%20(CONFIRM):%20A%20multicentre,%20double-blind,%20randomised,%20phase%203%20trial&amp;author=DA%20Fennell&amp;author=S%20Ewings&amp;author=C%20Ottensmeier&amp;volume=22&amp;issue=11&amp;publication_year=2021&amp;pages=1530-40&amp;pmid=34656227&amp;doi=10.1016/S1470-2045(21)00471-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b49-amjcaserep-26-e946585">
<span class="label">49.</span><cite>Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392. doi: 10.1038/s41467-022-27960-2.</cite> [<a href="https://doi.org/10.1038/s41467-022-27960-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8770784/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35046403/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Immune-related%20adverse%20events%20and%20the%20balancing%20act%20of%20immunotherapy&amp;author=M%20Conroy&amp;author=J%20Naidoo&amp;volume=13&amp;issue=1&amp;publication_year=2022&amp;pages=392&amp;pmid=35046403&amp;doi=10.1038/s41467-022-27960-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b50-amjcaserep-26-e946585">
<span class="label">50.</span><cite>Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9. doi: 10.4110/in.2020.20.e9.</cite> [<a href="https://doi.org/10.4110/in.2020.20.e9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7049586/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32158597/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Immune%20Netw&amp;title=Clinical%20characteristics%20and%20treatment%20of%20immune-related%20adverse%20events%20of%20immune%20checkpoint%20inhibitors&amp;author=J%20Choi&amp;author=SY%20Lee&amp;volume=20&amp;issue=1&amp;publication_year=2020&amp;pages=e9&amp;pmid=32158597&amp;doi=10.4110/in.2020.20.e9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b51-amjcaserep-26-e946585">
<span class="label">51.</span><cite>Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560–75. doi: 10.3978/j.issn.2218-6751.2015.06.06.</cite> [<a href="https://doi.org/10.3978/j.issn.2218-6751.2015.06.06" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4630514/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26629425/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Lung%20Cancer%20Res&amp;title=Immune%20checkpoint%20inhibitors%20in%20clinical%20practice:%20Update%20on%20management%20of%20immune-related%20toxicities&amp;author=J%20Villadolid&amp;author=A%20Amin&amp;volume=4&amp;issue=5&amp;publication_year=2015&amp;pages=560-75&amp;pmid=26629425&amp;doi=10.3978/j.issn.2218-6751.2015.06.06&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b52-amjcaserep-26-e946585">
<span class="label">52.</span><cite>Hodi FS, O’Day SJ, McDermott DF, et al.  Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi: 10.1056/NEJMoa1003466.</cite> [<a href="https://doi.org/10.1056/NEJMoa1003466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3549297/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20525992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&amp;author=FS%20Hodi&amp;author=SJ%20O%E2%80%99Day&amp;author=DF%20McDermott&amp;volume=363&amp;issue=8&amp;publication_year=2010&amp;pages=711-23&amp;pmid=20525992&amp;doi=10.1056/NEJMoa1003466&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b53-amjcaserep-26-e946585">
<span class="label">53.</span><cite>Robert C, Thomas L, Bondarenko I, et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi: 10.1056/NEJMoa1104621.</cite> [<a href="https://doi.org/10.1056/NEJMoa1104621" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21639810/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Ipilimumab%20plus%20dacarbazine%20for%20previously%20untreated%20metastatic%20melanoma&amp;author=C%20Robert&amp;author=L%20Thomas&amp;author=I%20Bondarenko&amp;volume=364&amp;issue=26&amp;publication_year=2011&amp;pages=2517-26&amp;pmid=21639810&amp;doi=10.1056/NEJMoa1104621&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b54-amjcaserep-26-e946585">
<span class="label">54.</span><cite>Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. doi: 10.1056/NEJMoa1503093.</cite> [<a href="https://doi.org/10.1056/NEJMoa1503093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25891173/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma&amp;author=C%20Robert&amp;author=J%20Schachter&amp;author=GV%20Long&amp;volume=372&amp;issue=26&amp;publication_year=2015&amp;pages=2521-32&amp;pmid=25891173&amp;doi=10.1056/NEJMoa1503093&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b55-amjcaserep-26-e946585">
<span class="label">55.</span><cite>Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017;24(12):T331–47. doi: 10.1530/ERC-17-0358.</cite> [<a href="https://doi.org/10.1530/ERC-17-0358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29025857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocr%20Relat%20Cancer&amp;title=Endocrine%20side%20effects%20of%20cancer%20immunotherapy&amp;author=P%20Cukier&amp;author=FC%20Santini&amp;author=M%20Scaranti&amp;author=AO%20Hoff&amp;volume=24&amp;issue=12&amp;publication_year=2017&amp;pages=T331-47&amp;pmid=29025857&amp;doi=10.1530/ERC-17-0358&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b56-amjcaserep-26-e946585">
<span class="label">56.</span><cite>de Filette J, Jansen Y, Schreuer M, et al.  Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101(11):4431–39. doi: 10.1210/jc.2016-2300.</cite> [<a href="https://doi.org/10.1210/jc.2016-2300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5095250/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27571185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&amp;title=Incidence%20of%20thyroid-related%20adverse%20events%20in%20melanoma%20patients%20treated%20with%20pembrolizumab&amp;author=J%20de%20Filette&amp;author=Y%20Jansen&amp;author=M%20Schreuer&amp;volume=101&amp;issue=11&amp;publication_year=2016&amp;pages=4431-39&amp;pmid=27571185&amp;doi=10.1210/jc.2016-2300&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b57-amjcaserep-26-e946585">
<span class="label">57.</span><cite>Mahmood SS, Fradley MG, Cohen JV, et al.  Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi: 10.1016/j.jacc.2018.02.037.</cite> [<a href="https://doi.org/10.1016/j.jacc.2018.02.037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6196725/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29567210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Myocarditis%20in%20patients%20treated%20with%20immune%20checkpoint%20inhibitors&amp;author=SS%20Mahmood&amp;author=MG%20Fradley&amp;author=JV%20Cohen&amp;volume=71&amp;issue=16&amp;publication_year=2018&amp;pages=1755-64&amp;pmid=29567210&amp;doi=10.1016/j.jacc.2018.02.037&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b58-amjcaserep-26-e946585">
<span class="label">58.</span><cite>Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–86. doi: 10.1634/theoncologist.2018-0130.</cite> [<a href="https://doi.org/10.1634/theoncologist.2018-0130" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6156176/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29802219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Immune%20checkpoint%20inhibitor-associated%20myocarditis&amp;author=S%20Ganatra&amp;author=TG%20Neilan&amp;volume=23&amp;issue=8&amp;publication_year=2018&amp;pages=879-86&amp;pmid=29802219&amp;doi=10.1634/theoncologist.2018-0130&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b59-amjcaserep-26-e946585">
<span class="label">59.</span><cite>Cortazar FB, Marrone KA, Troxell ML, et al.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–47. doi: 10.1016/j.kint.2016.04.008.</cite> [<a href="https://doi.org/10.1016/j.kint.2016.04.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4983464/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27282937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Clinicopathological%20features%20of%20acute%20kidney%20injury%20associated%20with%20immune%20checkpoint%20inhibitors&amp;author=FB%20Cortazar&amp;author=KA%20Marrone&amp;author=ML%20Troxell&amp;volume=90&amp;issue=3&amp;publication_year=2016&amp;pages=638-47&amp;pmid=27282937&amp;doi=10.1016/j.kint.2016.04.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b60-amjcaserep-26-e946585">
<span class="label">60.</span><cite>Naidoo J, Wang X, Woo KM, et al.  Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17. doi: 10.1200/JCO.2016.68.2005.</cite> [<a href="https://doi.org/10.1200/JCO.2016.68.2005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5559901/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27646942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&amp;title=Pneumonitis%20in%20patients%20treated%20with%20anti-programmed%20death-1/programmed%20death%20ligand%201%20therapy&amp;author=J%20Naidoo&amp;author=X%20Wang&amp;author=KM%20Woo&amp;volume=35&amp;issue=7&amp;publication_year=2017&amp;pages=709-17&amp;pmid=27646942&amp;doi=10.1200/JCO.2016.68.2005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b61-amjcaserep-26-e946585">
<span class="label">61.</span><cite>Nishino M, Sholl LM, Hodi FS, et al.  Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373(3):288–90. doi: 10.1056/NEJMc1505197.</cite> [<a href="https://doi.org/10.1056/NEJMc1505197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4539956/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26176400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Anti-PD-1-related%20pneumonitis%20during%20cancer%20immunotherapy&amp;author=M%20Nishino&amp;author=LM%20Sholl&amp;author=FS%20Hodi&amp;volume=373&amp;issue=3&amp;publication_year=2015&amp;pages=288-90&amp;pmid=26176400&amp;doi=10.1056/NEJMc1505197&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b62-amjcaserep-26-e946585">
<span class="label">62.</span><cite>Albarel F, Gaudy C, Castinetti F, et al.  Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195–204. doi: 10.1530/EJE-14-0845.</cite> [<a href="https://doi.org/10.1530/EJE-14-0845" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25416723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Endocrinol&amp;title=Long-term%20follow-up%20of%20ipilimumab-induced%20hypophysitis,%20a%20common%20adverse%20event%20of%20the%20anti-CTLA-4%20antibody%20in%20melanoma&amp;author=F%20Albarel&amp;author=C%20Gaudy&amp;author=F%20Castinetti&amp;volume=172&amp;issue=2&amp;publication_year=2015&amp;pages=195-204&amp;pmid=25416723&amp;doi=10.1530/EJE-14-0845&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b63-amjcaserep-26-e946585">
<span class="label">63.</span><cite>Lee CH, Motzer RJ. Immune checkpoint therapy in renal cell carcinoma. Cancer J. 2016;22(2):92–95. doi: 10.1097/PPO.0000000000000177.</cite> [<a href="https://doi.org/10.1097/PPO.0000000000000177" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27111903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20J&amp;title=Immune%20checkpoint%20therapy%20in%20renal%20cell%20carcinoma&amp;author=CH%20Lee&amp;author=RJ%20Motzer&amp;volume=22&amp;issue=2&amp;publication_year=2016&amp;pages=92-95&amp;pmid=27111903&amp;doi=10.1097/PPO.0000000000000177&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b64-amjcaserep-26-e946585">
<span class="label">64.</span><cite>Remon J, Planchard D. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015;11(22):3069–81. doi: 10.2217/fon.15.250.</cite> [<a href="https://doi.org/10.2217/fon.15.250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26450446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Future%20Oncol&amp;title=AZD9291%20in%20EGFR-mutant%20advanced%20non-small-cell%20lung%20cancer%20patients&amp;author=J%20Remon&amp;author=D%20Planchard&amp;volume=11&amp;issue=22&amp;publication_year=2015&amp;pages=3069-81&amp;pmid=26450446&amp;doi=10.2217/fon.15.250&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b65-amjcaserep-26-e946585">
<span class="label">65.</span><cite>Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7(6):535–43. doi: 10.1093/humupd/7.6.535.</cite> [<a href="https://doi.org/10.1093/humupd/7.6.535" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11727861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Reprod%20Update&amp;title=The%20effects%20of%20radiotherapy%20and%20chemotherapy%20on%20female%20reproduction&amp;author=D%20Meirow&amp;author=D%20Nugent&amp;volume=7&amp;issue=6&amp;publication_year=2001&amp;pages=535-43&amp;pmid=11727861&amp;doi=10.1093/humupd/7.6.535&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b66-amjcaserep-26-e946585">
<span class="label">66.</span><cite>Gougis P, Hamy A-S, Jochum F, et al.  Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. JAMA Network Open. 2024;7(4):e245625. doi: 10.1001/jamanetworkopen.2024.5625.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2024.5625" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11024778/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38630478/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Network%20Open&amp;title=Immune%20checkpoint%20inhibitor%20use%20during%20pregnancy%20and%20outcomes%20in%20pregnant%20individuals%20and%20newborns&amp;author=P%20Gougis&amp;author=A-S%20Hamy&amp;author=F%20Jochum&amp;volume=7&amp;issue=4&amp;publication_year=2024&amp;pages=e245625&amp;pmid=38630478&amp;doi=10.1001/jamanetworkopen.2024.5625&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b67-amjcaserep-26-e946585">
<span class="label">67.</span><cite>Tripathy D, Im SA, Colleoni M, et al.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15. doi: 10.1016/S1470-2045(18)30292-4.</cite> [<a href="https://doi.org/10.1016/S1470-2045(18)30292-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29804902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&amp;title=Ribociclib%20plus%20endocrine%20therapy%20for%20premenopausal%20women%20with%20hormone-receptor-positive,%20advanced%20breast%20cancer%20(MONALEESA-7):%20A%20randomised%20phase%203%20trial&amp;author=D%20Tripathy&amp;author=SA%20Im&amp;author=M%20Colleoni&amp;volume=19&amp;issue=7&amp;publication_year=2018&amp;pages=904-15&amp;pmid=29804902&amp;doi=10.1016/S1470-2045(18)30292-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from The American Journal of Case Reports are provided here courtesy of <strong>International Scientific Information, Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.12659/AJCR.946585"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/amjcaserep-26-e946585.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (5.5 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11997901/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11997901/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11997901%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11997901/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11997901/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11997901/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40208846/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11997901/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40208846/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11997901/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11997901/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="HMxaUAENtxwtN53nHjgXFsFgJDcL9WZk27Rz4TY8Z75TZSOqLUieR9V6mF5ePvjP">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
